ClinicalTrials.gg
Active, not recruitingNCT03653507GLOWUpdated Sep 28, 2026Results posted

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

A Phase 3 interventional study of zolbetuximab and oxaliplatin in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer and Metastatic Gastric Adenocarcinoma or Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 165 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.

Started
2018
with 1 other
Phase 3
4 of 12
2 open now
Registered
3rd of 12
by date

Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is one of 2 that started in 2018, is one of 4 in phase 3, and was the 3rd registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Adenocarcinoma by Astellas Pharma Inc, or all of them as a file.
02

Study summary

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor.

There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat stomach cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the people taking part in those countries will leave this study and receive licensed zolbetuximab.

The main aim(s) of the study is(are) to determine the efficacy of zolbetuximab combined with chemotherapy compared to a placebo combined with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections.

The study treatments are either zolbetuximab with chemotherapy or placebo with chemotherapy. People who take part will receive just one of the treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. The chemotherapy is called CAPOX (capecitabine and oxaliplatin) and will be given as an infusion and also as tablets. People will have 1 infusion of either zolbetuximab or placebo together with oxaliplatin chemotherapy in 3-week (21-day) cycles. People will also take 1 tablet of capecitabine (chemotherapy) twice a day for the first 2 weeks (14 days) of each cycle. People may receive zolbetuximab or placebo until their cancer worsens, they cannot tolerate the treatment, or they need to start another cancer treatment. People will receive CAPOX for up to about 6 months (8 treatment cycles). After the 6 months, people may receive capecitabine chemotherapy only, until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will visit the clinic on certain days during their treatment. The study doctors will check if people had any medical problems from zolbetuximab or the other study treatments. Also, people in the study will have health checks. On some visits, they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample after their study treatment has finished. People will visit the clinic within 7 days after they stop their study treatment. People will be asked about any medical problems and will have a health check. People who start treatment with licensed zolbetuximab will not need to attend the clinic for further visits and will receive standard of care health checks. People who continue study treatment will visit the clinic at 1 and 3 months after they stop their study treatment. They will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.

Read the detailed description

After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.

03

Conditions studied

  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
  • Metastatic Gastric Adenocarcinoma or Cancer
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Keywords

  • CLDN 18.2
  • gastroesophageal junction cancer
  • adenocarcinoma
  • IMAB362
  • oxaliplatin
  • HER2
  • claudiximab
  • capecitabine
  • gastric cancer
  • HER2 Negative
  • zolbetuximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin (βhCG) and a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of the following conditions applies:

    • Not a woman of (WOCBP) OR
    • WOCBP who agrees to follow the guidance throughout the treatment period and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study treatment administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs.
  • A male subject with female partner(s) of childbearing potential:

    • must agree to use contraception during the treatment period and for 6 months after the final study treatment administration.
  • A male subject must not donate sperm during the treatment period and for 6 months after the final study treatment administration.
  • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study treatment administration.
  • Subject has confirmed diagnosis of Gastric or GEJ adenocarcinoma.
  • Subject has radiologically confirmed locally advanced unresectable or disease within 28 days prior to randomization.
  • Subject has radiologically evaluable disease (measurable and/or non- according to 1.1), per local assessment, ≤ 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy.
  • Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing.
  • Subject has a -negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.)
  • Subject has performance status 0 or 1.
  • Subject has predicted ≥ 12 weeks.
  • Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility.

    • (Hb) ≥ 9 g/dl. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb ≥ 9 g/dL.
    • (ANC) ≥ 1.5x10\^9/L
    • ≥ 100x10\^9/L
    • Albumin ≥ 2.5 g/dL
    • Total ≤ 1.5 x (ULN) without liver metastases (or \< 3.0 x ULN if liver metastases are present)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present)
    • Estimated ≥ 30 mL/min
    • /international normalized ratio (PT/INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion criteria

Exclusion Criteria:

  • Subject has received prior systemic chemotherapy for locally advanced unresectable or gastric or GEJ adenocarcinoma. However, subject may have received either or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to randomization.
  • Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity.
  • Subject has received treatment with herbal medications or other treatments that have known antitumor activity within 28 days prior to randomization.
  • Subject has received systemic therapy, including systemic within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.
  • Subject has received other agents or devices within 28 days prior to randomization.
  • Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.
  • Subject has known immediate or delayed , intolerance or to any component of study treatment.
  • Subject has prior severe allergic reaction or intolerance to any component of CAPOX.
  • Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  • Subject has significant gastric bleeding and/or untreated gastric ulcers that exclude the subject from participation.
  • Subject has a known history of a positive test for (HIV) infection or known active (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements.

    • For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded.
    • Subjects with positive virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible.
    • Subjects treated for HCV with undetectable viral load results are eligible.
  • Subject has an active disease that has required systemic treatment within the past 3 months prior to randomization.
  • Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization.
  • Subject has significant cardiovascular disease, including any of the following:

    • Congestive heart failure (defined as Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization.
    • History of ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes
    • > 450 msec for male subjects; QTc interval > 470 msec for female subjects
    • History or family history of congenital long QT syndrome
    • Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > 1 month prior to randomization are eligible).
  • Subject has a history of central nervous system (CNS) metastases and/or carcinomatous meningitis from gastric/GEJ cancer..
  • Subject has known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.
  • Subject has had a major surgical procedure ≤ 28 days prior to randomization.

    • Subject is without complete recovery from a major surgical procedure ≤ 14 days prior to randomization.
  • Subject has psychiatric illness or social situations that would preclude study compliance.
  • Subject has another for which treatment is required.
  • Subject has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Zolbetuximab plus CAPOX

    Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.

    Drug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine

  • Placebo comparator
    Placebo plus CAPOX

    Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.

    Drug: oxaliplatin · Drug: capecitabine · Drug: placebo

Interventions

  • Zolbetuximab were administered as a minimum 2-hour IV infusion.

    Also known as: IMAB362

  • Oxaliplatin were administered as a 2-hour IV infusion.

  • Capecitabine were administered orally twice daily (bid).

  • Drugplacebo

    Placebo were administered as a minimum 2-hour IV infusion.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.

    Time frame: From the date of randomization until 61 months and 12 days

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.

    Time frame: From the date of randomization until 61 months and 12 days

  2. Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)

    TTCD: time from randomization to first clinically meaning full deterioration (CMFD) that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's change from baseline (CFB) exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.

    Time frame: From the date of randomization until 61 months and 12 days

  3. Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale

    TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used

    Time frame: From the date of randomization until 61 months and 12 days

  4. Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30

    TTCD: time from randomization to first CMFD that was confirmed at the next scheduled visit.The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's CFB exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.

    Time frame: From the date of randomization until 61 months and 12 days

  5. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

    Time frame: From the date of randomization until 61 months and 12 days

  6. Duration Of Response (DOR)

    DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.

    Time frame: From first response (CR/PR) until 61 months and 12 days

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

    Time frame: From first dose until 61 months and 12 days

  8. Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status

    ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: Baseline, cycle (C) 1 day (D)1 through C60 D1

  9. Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire

    The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.It is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.

    Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up

  10. Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire

    OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain \& discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100;higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25.

    Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up

  11. Change From Baseline in HRQoL Measured by Global Pain (GP)

    The GP instrument is a single assessment of overall pain and participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain. Low pain scores are considered a better outcome than a high pain score.

    Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up

  12. Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire

    EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status. It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

    Time frame: Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up

  13. Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)

    Ctrough was defined as the predose concentration at the end of dosing interval.

    Time frame: Predose on C2D1,C5D1,C9D1,C13D1,C17D1

  14. Number of Anti-drug Antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up

07

Results

Posted Jan 27, 2025

Participant flow

Participants with claudin (CLDN)18.2-positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma

Participant flow — Overall Study
MilestoneCAPOX+ ZolbetuximabCAPOX+ Placebo
Started254249
Completed92
Not completed245247
Withdrew: Miscellaneous2819
Withdrew: Withdrawal by subject3722
Withdrew: Protocol deviation21
Withdrew: Progressive disease117168
Withdrew: Lost to follow-up11
Withdrew: Death2522
Withdrew: Adverse event3514

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Progression Free Survival (PFS)8.21 (7.26 to 8.84)6.80 (6.14 to 8.08)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.0005 · Hazard ratio (hr): 0.689 · 95% CI 0.552 to 0.860Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Median · Months
Overall Survival (OS)
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Overall Survival (OS)14.32 (12.09 to 16.39)12.16 (10.28 to 13.67)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.0047 · Hazard ratio (hr): 0.763 · 95% CI 0.622 to 0.936Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryTime to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)

TTCD: time from randomization to first clinically meaning full deterioration (CMFD) that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's change from baseline (CFB) exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)7.95 (5.88 to 19.78)7.92 (6.47 to 11.30)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.4654 · Hazard ratio (hr): 1.012 · 95% CI 0.772 to 1.328Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryTime to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale

TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching SubscaleNA (28.16 to NA)25.82 (18.46 to NA)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.4478 · Hazard ratio (hr): 1.030 · 95% CI 0.673 to 1.577Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryTime to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30

TTCD: time from randomization to first CMFD that was confirmed at the next scheduled visit.The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 (very poor) to 7 (excellent). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Clinically meaningful deterioration was defined if a participant's CFB exceeded a pre-specified threshold (as per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used.

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C309.40 (7.36 to 24.80)7.49 (6.11 to 9.86)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.1670 · Hazard ratio (hr): 0.869 · 95% CI 0.655 to 1.153Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

Time frame:
From the date of randomization until 61 months and 12 days
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsCAPOX+ ZolbetuximabCAPOX+ Placebo
Objective Response Rate (ORR)42.5 (36.36 to 48.85)39.1 (33.08 to 45.44)
Statistical analysis
  • CAPOX+ Zolbetuximab · Cochran-Mantel-Haenszel · p = 0.2219 (Based on 1-sided Cochran-Mantel-Haenszel (CMH) test. Stratification factors were Region, Number of Metastatic Sites and Prior Gastrectomy.)
SecondaryDuration Of Response (DOR)

DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.

Time frame:
From first response (CR/PR) until 61 months and 12 days
Reported as:
Median · Months
Duration Of Response (DOR)
MonthsCAPOX+ ZolbetuximabCAPOX+ Placebo
Duration Of Response (DOR)6.28 (5.39 to 8.28)6.08 (4.44 to 6.34)
Statistical analysis
  • CAPOX+ Zolbetuximab · Log Rank · p = 0.0826 · Hazard ratio (hr): 0.781 · 95% CI 0.552 to 1.105Log-rank test stratified by:\* Region (Asia vs Non-Asia), \* Number of organs with metastatic sites (0 to 2 vs \>= 3), \* Prior gastrectomy (Yes or No)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

Time frame:
From first dose until 61 months and 12 days
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsCAPOX+ ZolbetuximabCAPOX+ Placebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)251 (NA to NA)244 (NA to NA)
SecondaryNumber of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status

ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

Time frame:
Baseline, cycle (C) 1 day (D)1 through C60 D1
Reported as:
Number · Participants
Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsCAPOX+ ZolbetuximabCAPOX+ Placebo
Baseline Score 0108108
Baseline Score 1145142
Baseline Score 200
Baseline Score 300
Baseline Score 400
Baseline Score 500
C2D1 Score 08597
C2D1 Score 1129126
C2D1 Score 252
C2D1 Score 300
C2D1 Score 400
C2D1 Score 500
C3D1 Score 08091
C3D1 Score 1116117
C3D1 Score 202
C3D1 Score 300
C3D1 Score 400
C3D1 Score 500
C4D1 Score 07479
C4D1 Score 110698
C4D1 Score 202
C4D1 Score 300
C4D1 Score 400
C4D1 Score 500
C5D1 Score 06875
C5D1 Score 19898
C5D1 Score 222
C5D1 Score 300
C5D1 Score 400
C5D1 Score 500
C6D1 Score 07172
C6D1 Score 18680
C6D1 Score 223
C6D1 Score 301
C6D1 Score 400
C6D1 Score 500
C7D1 Score 05260
C7D1 Score 16776
C7D1 Score 220
C7D1 Score 310
C7D1 Score 400
C7D1 Score 500
C8D1 Score 04944
C8D1 Score 16370
C8D1 Score 210
C8D1 Score 300
C8D1 Score 400
C8D1 Score 500
C9D1 Score 04747
C9D1 Score 15759
C9D1 Score 220
C9D1 Score 300
C9D1 Score 400
C9D1 Score 500
C10D1 Score 03940
C10D1 Score 14744
C10D1 Score 220
C10D1 Score 300
C10D1 Score 400
C10D1 Score 500
C11D1 Score 04134
C11D1 Score 14543
C11D1 Score 200
C11D1 Score 300
C11D1 Score 400
C11D1 Score 500
C12D1 Score 03929
C12D1 Score 13836
C12D1 Score 200
C12D1 Score 300
C12D1 Score 400
C12D1 Score 500
C13D1 Score 03324
C13D1 Score 13430
C13D1 Score 200
C13D1 Score 300
C13D1 Score 400
C13D1 Score 500
C14D1 Score 03220
C14D1 Score 13228
C14D1 Score 200
C14D1 Score 300
C14D1 Score 400
C14D1 Score 500
C15D1 Score 02416
C15D1 Score 13025
C15D1 Score 200
C15D1 Score 300
C15D1 Score 400
C15D1 Score 500
C16D1 Score 02318
C16D1 Score 12717
C16D1 Score 210
C16D1 Score 300
C16D1 Score 400
C16D1 Score 500
C17D1 Score 02217
C17D1 Score 12412
C17D1 Score 210
C17D1 Score 300
C17D1 Score 400
C17D1 Score 500
C18D1 Score 02616
C18D1 Score 1218
C18D1 Score 200
C18D1 Score 300
C18D1 Score 400
C18D1 Score 500
C19D1 Score 02214
C19D1 Score 1218
C19D1 Score 200
C19D1 Score 300
C19D1 Score 400
C19D1 Score 500
C20D1 Score 02415
C20D1 Score 1196
C20D1 Score 200
C20D1 Score 300
C20D1 Score 400
C20D1 Score 500
C21D1 Score 02315
C21D1 Score 1177
C21D1 Score 200
C21D1 Score 300
C21D1 Score 400
C21D1 Score 500
C22D1 Score 01712
C22D1 Score 1155
C22D1 Score 210
C22D1 Score 300
C22D1 Score 400
C22D1 Score 500
C23D1 Score 02014
C23D1 Score 1144
C23D1 Score 200
C23D1 Score 300
C23D1 Score 400
C23D1 Score 500
C24D1 Score 01911
C24D1 Score 1135
C24D1 Score 200
C24D1 Score 300
C24D1 Score 400
C24D1 Score 500
C25D1 Score 01711
C25D1 Score 1145
C25D1 Score 200
C25D1 Score 300
C25D1 Score 400
C25D1 Score 500
C26D1 Score 0198
C26D1 Score 1114
C26D1 Score 200
C26D1 Score 300
C26D1 Score 400
C26D1 Score 500
C27D1 Score 0178
C27D1 Score 1114
C27D1 Score 200
C27D1 Score 300
C27D1 Score 400
C27D1 Score 500
C28D1 Score 0178
C28D1 Score 174
C28D1 Score 200
C28D1 Score 300
C28D1 Score 400
C28D1 Score 500
C29D1 Score 0178
C29D1 Score 174
C29D1 Score 200
C29D1 Score 300
C29D1 Score 400
C29D1 Score 500
C30D1 Score 0154
C30D1 Score 174
C30D1 Score 200
C30D1 Score 300
C30D1 Score 400
C30D1 Score 500
C31D1 Score 0153
C31D1 Score 174
C31D1 Score 200
C31D1 Score 300
C31D1 Score 400
C31D1 Score 500
C32D1 Score 0134
C32D1 Score 164
C32D1 Score 200
C32D1 Score 300
C32D1 Score 400
C32D1 Score 500
C33D1 Score 0114
C33D1 Score 153
C33D1 Score 200
C33D1 Score 300
C33D1 Score 400
C33D1 Score 500
C34D1 Score 0114
C34D1 Score 133
C34D1 Score 200
C34D1 Score 300
C34D1 Score 400
C34D1 Score 500
C35D1 Score 0103
C35D1 Score 153
C35D1 Score 200
C35D1 Score 300
C35D1 Score 400
C35D1 Score 500
C36D1 Score 0101
C36D1 Score 163
C36D1 Score 200
C36D1 Score 300
C36D1 Score 400
C36D1 Score 500
C37D1 Score 093
C37D1 Score 151
C37D1 Score 200
C37D1 Score 300
C37D1 Score 400
C37D1 Score 500
C38D1 Score 082
C38D1 Score 151
C38D1 Score 200
C38D1 Score 300
C38D1 Score 400
C38D1 Score 500
C39D1 Score 081
C39D1 Score 130
C39D1 Score 200
C39D1 Score 300
C39D1 Score 400
C39D1 Score 500
C40D1 Score 081
C40D1 Score 130
C40D1 Score 200
C40D1 Score 300
C40D1 Score 400
C40D1 Score 500
C41D1 Score 081
C41D1 Score 130
C41D1 Score 200
C41D1 Score 300
C41D1 Score 400
C41D1 Score 500
C42D1 Score 071
C42D1 Score 130
C42D1 Score 200
C42D1 Score 300
C42D1 Score 400
C42D1 Score 500
C43D1 Score 051
C43D1 Score 120
C43D1 Score 200
C43D1 Score 300
C43D1 Score 400
C43D1 Score 500
C44D1 Score 071
C44D1 Score 120
C44D1 Score 200
C44D1 Score 300
C44D1 Score 400
C44D1 Score 500
C45D1 Score 071
C45D1 Score 120
C45D1 Score 200
C45D1 Score 300
C45D1 Score 400
C45D1 Score 500
C46D1 Score 07—
C46D1 Score 12—
C46D1 Score 20—
C46D1 Score 30—
C46D1 Score 40—
C46D1 Score 50—
C47D1 Score 06—
C47D1 Score 12—
C47D1 Score 20—
C47D1 Score 30—
C47D1 Score 40—
C47D1 Score 50—
C48D1 Score 05—
C48D1 Score 12—
C48D1 Score 20—
C48D1 Score 30—
C48D1 Score 40—
C48D1 Score 50—
C49D1 Score 03—
C49D1 Score 12—
C49D1 Score 20—
C49D1 Score 30—
C49D1 Score 40—
C49D1 Score 50—
C50D1 Score 02—
C50D1 Score 12—
C50D1 Score 20—
C50D1 Score 30—
C50D1 Score 40—
C50D1 Score 50—
C51D1 Score 02—
C51D1 Score 12—
C51D1 Score 20—
C51D1 Score 30—
C51D1 Score 40—
C51D1 Score 50—
C52D1 Score 02—
C52D1 Score 12—
C52D1 Score 20—
C52D1 Score 30—
C52D1 Score 40—
C52D1 Score 50—
C53D1 Score 02—
C53D1 Score 11—
C53D1 Score 20—
C53D1 Score 30—
C53D1 Score 40—
C53D1 Score 50—
C54D1 Score 02—
C54D1 Score 11—
C54D1 Score 20—
C54D1 Score 30—
C54D1 Score 40—
C54D1 Score 50—
C55D1 Score 01—
C55D1 Score 11—
C55D1 Score 20—
C55D1 Score 30—
C55D1 Score 40—
C55D1 Score 50—
C56D1 Score 01—
C56D1 Score 11—
C56D1 Score 20—
C56D1 Score 30—
C56D1 Score 40—
C56D1 Score 50—
C57D1 Score 01—
C57D1 Score 10—
C57D1 Score 20—
C57D1 Score 30—
C57D1 Score 40—
C57D1 Score 50—
C58D1 Score 01—
C58D1 Score 10—
C58D1 Score 20—
C58D1 Score 30—
C58D1 Score 40—
C58D1 Score 50—
C59D1 Score 01—
C59D1 Score 10—
C59D1 Score 20—
C59D1 Score 30—
C59D1 Score 40—
C59D1 Score 50—
C60D1 Score 01—
C60D1 Score 10—
C60D1 Score 20—
C60D1 Score 30—
C60D1 Score 40—
C60D1 Score 50—
SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire

The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.It is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ('not at all') to 4 ('very much') except for the items contributing to the global health status/QoL, which are scored 1 ('very poor') to 7 ('excellent'). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.

Time frame:
Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Reported as:
Mean · Unit on a scale
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
Unit on a scaleCAPOX+ ZolbetuximabCAPOX+ Placebo
Global Health Status Baseline68.83 ± 18.9466.15 ± 19.40
Global Health Status C2D10.04 ± 17.352.96 ± 18.89
Global Health Status C3D11.47 ± 17.153.68 ± 20.69
Global Health Status C4D12.61 ± 18.794.54 ± 20.59
Global Health Status C5D10.89 ± 20.963.48 ± 19.57
Global Health Status C6D10.84 ± 19.323.94 ± 20.51
Global Health Status C7D11.94 ± 18.292.12 ± 19.69
Global Health Status C8D10.77 ± 16.964.32 ± 20.31
Global Health Status C9D11.88 ± 20.913.32 ± 20.89
Global Health Status C10D12.65 ± 20.383.48 ± 22.23
Global Health Status C11D11.23 ± 21.893.99 ± 23.18
Global Health Status C12D12.44 ± 23.442.63 ± 22.06
Global Health Status C13D13.47 ± 24.223.30 ± 20.82
Global Health Status C14D11.52 ± 18.083.79 ± 21.15
Global Health Status C15D12.94 ± 22.782.08 ± 21.02
Global Health Status C16D13.65 ± 22.675.65 ± 17.40
Global Health Status C17D16.01 ± 19.363.33 ± 20.41
Global Health Status C18D13.66 ± 21.333.97 ± 31.36
Global Health Status C19D14.17 ± 17.5010.42 ± 15.97
Global Health Status C20D11.50 ± 17.723.95 ± 19.71
Global Health Status C21D14.17 ± 18.532.92 ± 18.98
Global Health Status C22D14.03 ± 19.719.31 ± 22.99
Global Health Status C23D14.03 ± 16.929.38 ± 19.69
Global Health Status C24D12.87 ± 19.329.72 ± 21.86
Global Health Status C25D11.79 ± 18.7510.42 ± 24.39
Global Health Status C26D14.81 ± 16.363.70 ± 19.59
Global Health Status C27D14.00 ± 18.186.67 ± 11.65
Global Health Status C28D11.98 ± 18.625.30 ± 14.08
Global Health Status C29D13.03 ± 14.214.86 ± 14.42
Global Health Status C30D12.92 ± 14.12—
Global Health Status C31D12.08 ± 19.28—
Global Health Status C32D12.78 ± 16.17—
Global Health Status C33D15.56 ± 17.72—
Global Health Status C34D18.33 ± 20.72—
Global Health Status C35D14.49 ± 17.88—
Global Health Status C36D12.78 ± 17.16—
Global Health Status C37D110.61 ± 15.85—
Global Health Status C38D18.33 ± 21.15—
Global Health Status C39D13.70 ± 13.89—
Global Health Status 30 day follow up-8.63 ± 25.10-10.68 ± 24.65
Global Health Status 90 day follow up-5.46 ± 21.19-4.96 ± 22.86
Physical Functioning Baseline83.79 ± 16.8583.55 ± 17.22
Physical Functioning C2D1-0.93 ± 14.62-0.77 ± 13.70
Physical Functioning C3D1-1.76 ± 14.13-0.07 ± 14.94
Physical Functioning C4D1-0.16 ± 14.251.07 ± 15.38
Physical Functioning C5D1-0.67 ± 15.320.24 ± 16.29
Physical Functioning C6D1-0.89 ± 15.47-0.96 ± 17.94
Physical Functioning C7D1-1.78 ± 16.050.21 ± 17.69
Physical Functioning C8D1-3.27 ± 15.51-1.33 ± 17.08
Physical Functioning C9D1-3.20 ± 17.84-0.84 ± 18.26
Physical Functioning C10D1-2.75 ± 17.13-2.28 ± 18.76
Physical Functioning C11D1-0.82 ± 15.00-0.09 ± 17.11
Physical Functioning C12D1-0.89 ± 17.31-0.70 ± 19.18
Physical Functioning C13D1-0.56 ± 18.590.97 ± 13.89
Physical Functioning C14D10.12 ± 15.951.21 ± 13.04
Physical Functioning C15D10.39 ± 14.200.00 ± 13.62
Physical Functioning C16D1-0.42 ± 14.770.86 ± 12.14
Physical Functioning C17D12.33 ± 14.612.13 ± 16.75
Physical Functioning C18D1-2.93 ± 17.323.49 ± 15.44
Physical Functioning C19D11.33 ± 10.484.00 ± 13.40
Physical Functioning C20D1-0.85 ± 11.962.81 ± 16.68
Physical Functioning C21D1-0.74 ± 13.313.33 ± 12.89
Physical Functioning C22D1-0.22 ± 12.115.49 ± 17.52
Physical Functioning C23D1-0.22 ± 14.355.83 ± 19.30
Physical Functioning C24D12.30 ± 14.615.56 ± 17.71
Physical Functioning C25D10.48 ± 17.403.89 ± 23.35
Physical Functioning C26D11.28 ± 17.282.96 ± 17.36
Physical Functioning C27D11.07 ± 16.522.00 ± 13.72
Physical Functioning C28D1-1.27 ± 16.55-1.82 ± 19.80
Physical Functioning C29D1-3.33 ± 23.251.11 ± 18.16
Physical Functioning C30D11.67 ± 16.17—
Physical Functioning C31D12.00 ± 16.91—
Physical Functioning C32D1-1.11 ± 19.97—
Physical Functioning C33D12.22 ± 18.11—
Physical Functioning C34D16.67 ± 17.98—
Physical Functioning C35D17.18 ± 18.55—
Physical Functioning C36D16.67 ± 17.98—
Physical Functioning C37D17.27 ± 17.24—
Physical Functioning C38D16.67 ± 21.55—
Physical Functioning C39D12.96 ± 10.06—
Physical Functioning 30 day follow up-8.65 ± 22.36-9.91 ± 20.29
Physical Functioning 90 day follow up-10.16 ± 20.28-10.63 ± 22.28
Role Functioning Baseline83.20 ± 22.5282.23 ± 23.59
Role Functioning C2D1-2.64 ± 20.52-1.92 ± 19.97
Role Functioning C3D1-2.38 ± 21.82-2.28 ± 24.38
Role Functioning C4D1-2.37 ± 20.36-0.79 ± 24.65
Role Functioning C5D1-0.94 ± 20.73-0.40 ± 25.03
Role Functioning C6D1-3.69 ± 22.91-3.08 ± 24.68
Role Functioning C7D1-2.08 ± 20.68-0.79 ± 23.74
Role Functioning C8D1-5.25 ± 21.57-5.61 ± 26.16
Role Functioning C9D1-5.39 ± 23.71-2.59 ± 23.89
Role Functioning C10D1-3.92 ± 24.89-3.59 ± 26.91
Role Functioning C11D1-3.50 ± 19.31-3.29 ± 28.40
Role Functioning C12D1-3.33 ± 23.89-2.63 ± 26.69
Role Functioning C13D1-0.83 ± 24.44-0.35 ± 27.39
Role Functioning C14D1-1.21 ± 21.480.76 ± 21.25
Role Functioning C15D1-0.65 ± 21.07-0.46 ± 24.72
Role Functioning C16D11.74 ± 23.120.00 ± 21.08
Role Functioning C17D13.10 ± 22.502.67 ± 28.74
Role Functioning C18D1-3.25 ± 20.496.35 ± 21.39
Role Functioning C19D1-0.42 ± 20.506.67 ± 17.44
Role Functioning C20D11.28 ± 20.3710.53 ± 22.37
Role Functioning C21D1-0.93 ± 20.296.67 ± 23.82
Role Functioning C22D10.54 ± 19.488.82 ± 24.38
Role Functioning C23D10.00 ± 18.769.37 ± 30.41
Role Functioning C24D10.00 ± 18.376.94 ± 27.02
Role Functioning C25D11.79 ± 20.958.33 ± 28.87
Role Functioning C26D1-0.64 ± 20.81-3.70 ± 27.36
Role Functioning C27D10.00 ± 17.35-3.33 ± 23.31
Role Functioning C28D11.59 ± 18.18-4.55 ± 21.20
Role Functioning C29D1-1.52 ± 24.622.78 ± 19.89
Role Functioning C30D13.33 ± 19.19—
Role Functioning C31D17.50 ± 21.27—
Role Functioning C32D15.56 ± 23.57—
Role Functioning C33D16.67 ± 20.70—
Role Functioning C34D19.72 ± 24.06—
Role Functioning C35D17.69 ± 21.10—
Role Functioning C36D19.72 ± 21.86—
Role Functioning C37D112.12 ± 23.68—
Role Functioning C38D113.33 ± 21.94—
Role Functioning C39D17.41 ± 22.22—
Role Functioning 30 day follow up-13.16 ± 27.95-16.88 ± 31.38
Role Functioning 90 day follow up-10.93 ± 27.03-9.49 ± 30.39
Emotional Functioning Baseline80.42 ± 19.1378.79 ± 19.41
Emotional Functioning C2D11.32 ± 15.924.42 ± 16.49
Emotional Functioning C3D10.05 ± 16.213.00 ± 18.84
Emotional Functioning C4D12.42 ± 15.522.51 ± 19.52
Emotional Functioning C5D12.46 ± 17.353.69 ± 17.81
Emotional Functioning C6D11.79 ± 15.963.77 ± 19.18
Emotional Functioning C7D13.54 ± 17.902.12 ± 21.24
Emotional Functioning C8D10.77 ± 19.152.20 ± 18.08
Emotional Functioning C9D12.53 ± 19.192.59 ± 19.07
Emotional Functioning C10D15.20 ± 21.131.79 ± 20.62
Emotional Functioning C11D15.35 ± 20.472.58 ± 20.97
Emotional Functioning C12D16.44 ± 19.932.05 ± 21.49
Emotional Functioning C13D16.11 ± 20.401.91 ± 21.42
Emotional Functioning C14D13.94 ± 19.96-1.33 ± 18.76
Emotional Functioning C15D14.25 ± 16.61-1.85 ± 21.19
Emotional Functioning C16D13.99 ± 15.75-0.27 ± 23.22
Emotional Functioning C17D15.81 ± 15.165.33 ± 16.12
Emotional Functioning C18D12.24 ± 15.593.97 ± 19.65
Emotional Functioning C19D15.00 ± 15.074.58 ± 13.10
Emotional Functioning C20D13.85 ± 15.401.75 ± 19.95
Emotional Functioning C21D13.94 ± 18.315.00 ± 18.22
Emotional Functioning C22D14.30 ± 14.252.45 ± 18.58
Emotional Functioning C23D12.42 ± 11.423.65 ± 23.56
Emotional Functioning C24D12.59 ± 14.79-0.69 ± 23.96
Emotional Functioning C25D12.68 ± 16.36-0.69 ± 20.24
Emotional Functioning C26D14.17 ± 16.37-3.70 ± 18.69
Emotional Functioning C27D13.00 ± 18.30-5.83 ± 19.66
Emotional Functioning C28D10.79 ± 19.53-3.79 ± 19.85
Emotional Functioning C29D12.65 ± 17.33-3.47 ± 27.17
Emotional Functioning C30D1-0.42 ± 17.41—
Emotional Functioning C31D11.25 ± 17.16—
Emotional Functioning C32D13.70 ± 16.96—
Emotional Functioning C33D15.56 ± 18.81—
Emotional Functioning C34D111.81 ± 12.03—
Emotional Functioning C35D15.13 ± 15.79—
Emotional Functioning C36D19.03 ± 15.27—
Emotional Functioning C37D111.36 ± 15.93—
Emotional Functioning C38D110.83 ± 14.72—
Emotional Functioning C39D1-1.85 ± 21.15—
Emotional Functioning 30 day follow up-5.99 ± 26.01-5.02 ± 24.15
Emotional Functioning 90 day follow up-4.37 ± 15.340.21 ± 21.88
Cognitive Functioning Baseline90.95 ± 14.8687.81 ± 18.01
Cognitive Functioning C2D1-0.24 ± 13.360.54 ± 15.50
Cognitive Functioning C3D1-1.47 ± 14.900.51 ± 15.51
Cognitive Functioning C4D1-0.59 ± 13.471.87 ± 15.58
Cognitive Functioning C5D1-1.89 ± 15.802.22 ± 15.13
Cognitive Functioning C6D1-1.45 ± 14.870.91 ± 16.81
Cognitive Functioning C7D10.00 ± 16.31-1.19 ± 17.02
Cognitive Functioning C8D1-2.16 ± 15.130.15 ± 18.27
Cognitive Functioning C9D1-1.96 ± 14.700.97 ± 18.05
Cognitive Functioning C10D1-0.59 ± 17.15-0.42 ± 19.61
Cognitive Functioning C11D1-1.23 ± 14.86-1.41 ± 18.42
Cognitive Functioning C12D1-0.22 ± 13.831.17 ± 16.62
Cognitive Functioning C13D1-0.28 ± 15.190.69 ± 22.00
Cognitive Functioning C14D10.61 ± 15.700.00 ± 19.02
Cognitive Functioning C15D1-0.98 ± 15.06-1.39 ± 19.67
Cognitive Functioning C16D11.39 ± 16.43-2.69 ± 20.68
Cognitive Functioning C17D10.78 ± 12.572.67 ± 14.97
Cognitive Functioning C18D11.63 ± 13.852.38 ± 16.06
Cognitive Functioning C19D10.42 ± 16.663.33 ± 11.60
Cognitive Functioning C20D10.85 ± 17.911.75 ± 21.44
Cognitive Functioning C21D10.93 ± 19.086.67 ± 18.26
Cognitive Functioning C22D12.69 ± 18.314.90 ± 20.21
Cognitive Functioning C23D11.61 ± 17.936.25 ± 17.08
Cognitive Functioning C24D12.30 ± 18.750.00 ± 15.89
Cognitive Functioning C25D11.79 ± 18.891.39 ± 19.41
Cognitive Functioning C26D11.92 ± 19.050.00 ± 16.67
Cognitive Functioning C27D12.67 ± 17.13-1.67 ± 14.59
Cognitive Functioning C28D13.17 ± 18.72-3.03 ± 14.56
Cognitive Functioning C29D10.76 ± 21.500.00 ± 14.21
Cognitive Functioning C30D10.00 ± 18.73—
Cognitive Functioning C31D10.00 ± 18.73—
Cognitive Functioning C32D12.78 ± 21.58—
Cognitive Functioning C33D15.56 ± 20.57—
Cognitive Functioning C34D16.94 ± 21.86—
Cognitive Functioning C35D16.41 ± 24.09—
Cognitive Functioning C36D18.33 ± 19.46—
Cognitive Functioning C37D19.09 ± 21.56—
Cognitive Functioning C38D18.33 ± 23.90—
Cognitive Functioning C39D11.85 ± 13.03—
Cognitive Functioning 30 day follow up-2.63 ± 18.84-4.27 ± 20.18
Cognitive Functioning 90 day follow up-7.65 ± 17.37-2.32 ± 20.28
Social Functioning Baseline79.42 ± 22.1679.55 ± 23.48
Social Functioning C2D10.88 ± 21.31-1.61 ± 20.88
Social Functioning C3D1-1.47 ± 23.65-1.44 ± 22.70
Social Functioning C4D10.79 ± 23.771.97 ± 21.73
Social Functioning C5D12.20 ± 25.580.20 ± 22.31
Social Functioning C6D1-0.78 ± 25.29-1.37 ± 22.53
Social Functioning C7D1-0.97 ± 26.22-0.66 ± 24.71
Social Functioning C8D1-0.93 ± 27.33-2.12 ± 23.58
Social Functioning C9D1-0.98 ± 24.01-0.32 ± 24.47
Social Functioning C10D12.55 ± 25.39-0.84 ± 27.20
Social Functioning C11D13.29 ± 23.19-2.58 ± 25.14
Social Functioning C12D13.33 ± 23.09-1.75 ± 28.12
Social Functioning C13D13.89 ± 24.43-0.35 ± 23.19
Social Functioning C14D12.12 ± 20.801.52 ± 24.86
Social Functioning C15D11.63 ± 22.42-2.78 ± 23.06
Social Functioning C16D14.86 ± 20.031.08 ± 19.21
Social Functioning C17D15.43 ± 18.453.33 ± 15.96
Social Functioning C18D10.81 ± 22.962.38 ± 16.90
Social Functioning C19D15.42 ± 19.028.33 ± 20.59
Social Functioning C20D12.56 ± 21.817.02 ± 20.27
Social Functioning C21D12.31 ± 21.884.17 ± 17.83
Social Functioning C22D15.91 ± 21.324.90 ± 15.33
Social Functioning C23D14.30 ± 24.338.33 ± 18.26
Social Functioning C24D14.02 ± 23.84-1.39 ± 15.01
Social Functioning C25D14.76 ± 21.21-2.78 ± 15.62
Social Functioning C26D15.77 ± 23.543.70 ± 24.69
Social Functioning C27D14.00 ± 25.595.00 ± 15.81
Social Functioning C28D14.76 ± 29.883.03 ± 16.36
Social Functioning C29D13.03 ± 26.550.00 ± 21.32
Social Functioning C30D13.33 ± 28.41—
Social Functioning C31D13.33 ± 27.36—
Social Functioning C32D10.93 ± 29.41—
Social Functioning C33D13.33 ± 34.04—
Social Functioning C34D15.56 ± 35.06—
Social Functioning C35D12.56 ± 32.52—
Social Functioning C36D15.56 ± 33.58—
Social Functioning C37D16.06 ± 36.72—
Social Functioning C38D113.33 ± 31.23—
Social Functioning C39D10.00 ± 33.33—
Social Functioning 30 day follow up-4.09 ± 28.22-12.82 ± 26.03
Social Functioning 90 day follow up0.27 ± 24.05-8.23 ± 26.40
Fatigue Baseline26.29 ± 22.0027.55 ± 22.43
Fatigue C2D11.66 ± 19.690.15 ± 19.11
Fatigue C3D13.17 ± 21.710.96 ± 21.26
Fatigue C4D11.05 ± 21.93-0.46 ± 22.03
Fatigue C5D11.40 ± 23.21-0.81 ± 23.52
Fatigue C6D12.83 ± 21.070.91 ± 25.25
Fatigue C7D11.11 ± 20.99-1.06 ± 23.11
Fatigue C8D14.94 ± 20.340.10 ± 23.05
Fatigue C9D11.96 ± 24.94-0.86 ± 23.06
Fatigue C10D11.57 ± 25.67-0.42 ± 24.81
Fatigue C11D1-0.14 ± 22.53-0.31 ± 24.34
Fatigue C12D1-0.89 ± 24.080.00 ± 23.19
Fatigue C13D1-3.70 ± 25.030.00 ± 20.76
Fatigue C14D1-2.22 ± 19.99-0.76 ± 19.82
Fatigue C15D1-3.27 ± 21.12-0.62 ± 17.20
Fatigue C16D1-4.63 ± 21.60-2.15 ± 17.55
Fatigue C17D1-2.07 ± 18.98-1.78 ± 18.61
Fatigue C18D1-0.81 ± 17.10-7.94 ± 17.26
Fatigue C19D1-1.11 ± 17.93-4.44 ± 15.46
Fatigue C20D10.57 ± 16.51-4.68 ± 18.64
Fatigue C21D11.23 ± 16.75-3.33 ± 18.77
Fatigue C22D1-2.87 ± 19.02-3.27 ± 18.33
Fatigue C23D1-1.43 ± 17.62-4.17 ± 22.18
Fatigue C24D1-1.15 ± 17.65-3.70 ± 19.73
Fatigue C25D1-3.17 ± 18.36-0.93 ± 17.38
Fatigue C26D1-1.71 ± 21.700.00 ± 11.11
Fatigue C27D1-3.11 ± 14.172.22 ± 15.54
Fatigue C28D1-2.65 ± 16.068.08 ± 13.23
Fatigue C29D1-3.54 ± 14.705.56 ± 18.65
Fatigue C30D1-2.78 ± 13.90—
Fatigue C31D1-2.22 ± 17.14—
Fatigue C32D1-5.56 ± 18.77—
Fatigue C33D1-8.15 ± 19.91—
Fatigue C34D1-12.04 ± 18.63—
Fatigue C35D1-10.26 ± 12.39—
Fatigue C36D1-12.04 ± 10.00—
Fatigue C37D1-12.12 ± 14.45—
Fatigue C38D1-12.22 ± 21.24—
Fatigue C39D1-7.41 ± 19.25—
Fatigue 30 day follow up11.50 ± 23.0913.68 ± 27.15
Fatigue 90 day follow up11.84 ± 21.557.31 ± 22.00
Nausea and Vomiting Baseline10.49 ± 18.0815.08 ± 23.20
Nausea and Vomiting C2D16.41 ± 19.77-0.92 ± 20.77
Nausea and Vomiting C3D15.86 ± 19.880.17 ± 22.21
Nausea and Vomiting C4D14.73 ± 20.67-2.76 ± 22.98
Nausea and Vomiting C5D14.93 ± 21.01-3.74 ± 25.06
Nausea and Vomiting C6D16.04 ± 20.25-1.60 ± 24.71
Nausea and Vomiting C7D11.25 ± 19.94-2.91 ± 24.59
Nausea and Vomiting C8D13.09 ± 20.14-6.97 ± 23.83
Nausea and Vomiting C9D11.80 ± 20.83-6.15 ± 20.74
Nausea and Vomiting C10D10.39 ± 20.25-7.17 ± 24.99
Nausea and Vomiting C11D1-1.65 ± 19.65-6.81 ± 24.17
Nausea and Vomiting C12D1-1.11 ± 19.82-2.34 ± 25.48
Nausea and Vomiting C13D1-3.33 ± 20.54-7.99 ± 23.82
Nausea and Vomiting C14D1-1.21 ± 19.73-4.17 ± 21.00
Nausea and Vomiting C15D1-2.94 ± 18.17-5.56 ± 20.31
Nausea and Vomiting C16D1-1.04 ± 20.17-5.91 ± 20.43
Nausea and Vomiting C17D1-1.94 ± 18.622.67 ± 13.33
Nausea and Vomiting C18D10.81 ± 20.40-4.76 ± 11.95
Nausea and Vomiting C19D10.00 ± 20.32-4.17 ± 11.94
Nausea and Vomiting C20D1-0.85 ± 19.10-4.39 ± 12.22
Nausea and Vomiting C21D10.00 ± 19.92-3.33 ± 11.60
Nausea and Vomiting C22D1-2.69 ± 20.23-5.88 ± 13.10
Nausea and Vomiting C23D1-3.76 ± 21.39-7.29 ± 12.12
Nausea and Vomiting C24D1-3.45 ± 20.11-1.39 ± 11.14
Nausea and Vomiting C25D1-4.17 ± 20.60-6.94 ± 13.22
Nausea and Vomiting C26D1-4.49 ± 20.85-1.85 ± 24.22
Nausea and Vomiting C27D1-4.67 ± 20.14-5.00 ± 15.81
Nausea and Vomiting C28D1-0.79 ± 23.85-3.03 ± 14.56
Nausea and Vomiting C29D1-3.79 ± 21.78-9.72 ± 13.22
Nausea and Vomiting C30D1-3.33 ± 21.36—
Nausea and Vomiting C31D1-4.17 ± 23.49—
Nausea and Vomiting C32D1-2.78 ± 25.72—
Nausea and Vomiting C33D1-8.89 ± 21.70—
Nausea and Vomiting C34D1-8.33 ± 25.13—
Nausea and Vomiting C35D1-6.41 ± 25.04—
Nausea and Vomiting C36D1-6.94 ± 25.08—
Nausea and Vomiting C37D1-9.09 ± 20.23—
Nausea and Vomiting C38D1-6.67 ± 14.05—
Nausea and Vomiting C39D1-5.56 ± 8.33—
Nausea and Vomiting 30 day follow up4.39 ± 19.800.21 ± 24.25
Nausea and Vomiting 90 day follow up7.38 ± 21.20-1.05 ± 26.06
Pain Baseline21.67 ± 22.1424.10 ± 23.71
Pain C2D1-4.17 ± 22.43-4.61 ± 20.08
Pain C3D1-5.40 ± 21.16-3.38 ± 22.77
Pain C4D1-7.10 ± 21.18-7.40 ± 22.41
Pain C5D1-4.82 ± 22.06-6.26 ± 26.05
Pain C6D1-3.13 ± 19.79-6.85 ± 26.09
Pain C7D1-6.39 ± 22.16-7.67 ± 22.57
Pain C8D1-4.17 ± 22.22-5.61 ± 24.96
Pain C9D1-5.07 ± 21.72-8.09 ± 24.46
Pain C10D1-4.12 ± 22.11-6.33 ± 25.50
Pain C11D1-6.38 ± 21.01-6.34 ± 26.78
Pain C12D1-4.44 ± 22.48-7.02 ± 24.99
Pain C13D1-6.39 ± 23.98-7.64 ± 24.54
Pain C14D1-5.76 ± 22.27-6.06 ± 24.14
Pain C15D1-6.54 ± 19.17-7.41 ± 21.25
Pain C16D1-6.25 ± 19.64-6.45 ± 23.04
Pain C17D1-5.04 ± 19.43-7.33 ± 25.95
Pain C18D1-1.63 ± 18.18-11.90 ± 27.96
Pain C19D1-2.50 ± 18.32-7.50 ± 26.20
Pain C20D1-0.85 ± 16.64-8.77 ± 30.11
Pain C21D1-2.31 ± 19.58-11.67 ± 29.17
Pain C22D1-2.69 ± 18.31-12.75 ± 30.35
Pain C23D1-3.76 ± 18.11-15.63 ± 30.10
Pain C24D1-4.02 ± 18.18-8.33 ± 29.73
Pain C25D1-1.19 ± 21.24-11.11 ± 29.59
Pain C26D1-3.85 ± 19.61-9.26 ± 18.84
Pain C27D1-4.00 ± 20.57-6.67 ± 23.83
Pain C28D1-4.76 ± 21.18-3.03 ± 19.46
Pain C29D1-3.79 ± 21.16-11.11 ± 23.92
Pain C30D1-6.67 ± 19.79—
Pain C31D1-6.67 ± 21.90—
Pain C32D1-6.48 ± 22.97—
Pain C33D1-10.00 ± 22.54—
Pain C34D1-13.89 ± 21.12—
Pain C35D1-10.26 ± 22.09—
Pain C36D1-12.50 ± 21.47—
Pain C37D1-12.12 ± 23.68—
Pain C38D1-5.00 ± 24.91—
Pain C39D1-9.26 ± 16.90—
Pain 30 day follow up4.97 ± 27.458.76 ± 26.42
Pain 90 day follow up4.37 ± 22.552.11 ± 22.70
Dyspnoea Baseline9.74 ± 17.9610.88 ± 19.35
Dyspnoea C2D12.24 ± 15.89-0.77 ± 17.99
Dyspnoea C3D1-0.37 ± 16.800.51 ± 22.20
Dyspnoea C4D10.00 ± 16.67-0.39 ± 23.28
Dyspnoea C5D1-0.42 ± 19.48-2.22 ± 23.03
Dyspnoea C6D11.12 ± 19.540.00 ± 21.80
Dyspnoea C7D11.67 ± 20.20-0.53 ± 22.70
Dyspnoea C8D11.85 ± 19.252.12 ± 23.58
Dyspnoea C9D10.65 ± 18.15-2.27 ± 20.49
Dyspnoea C10D11.18 ± 20.86-0.42 ± 24.16
Dyspnoea C11D10.41 ± 20.07-3.29 ± 21.20
Dyspnoea C12D1-1.33 ± 20.09-2.92 ± 19.19
Dyspnoea C13D1-0.56 ± 23.36-2.78 ± 21.56
Dyspnoea C14D1-0.61 ± 20.78-4.55 ± 19.81
Dyspnoea C15D10.00 ± 17.64-4.63 ± 16.24
Dyspnoea C16D1-0.69 ± 16.11-3.23 ± 21.70
Dyspnoea C17D10.00 ± 16.27-6.67 ± 21.52
Dyspnoea C18D11.63 ± 16.59-9.52 ± 18.69
Dyspnoea C19D10.00 ± 16.88-11.67 ± 19.57
Dyspnoea C20D12.56 ± 19.32-10.53 ± 22.37
Dyspnoea C21D10.93 ± 16.88-10.00 ± 19.04
Dyspnoea C22D11.08 ± 20.15-9.80 ± 22.87
Dyspnoea C23D10.00 ± 14.91-8.33 ± 22.77
Dyspnoea C24D10.00 ± 17.82-5.56 ± 19.25
Dyspnoea C25D10.00 ± 20.29-5.56 ± 19.25
Dyspnoea C26D1-3.85 ± 14.38-7.41 ± 14.70
Dyspnoea C27D12.67 ± 16.44-6.67 ± 14.05
Dyspnoea C28D1-1.59 ± 16.59-9.09 ± 21.56
Dyspnoea C29D17.58 ± 27.08-11.11 ± 21.71
Dyspnoea C30D10.00 ± 18.73—
Dyspnoea C31D1-1.67 ± 22.88—
Dyspnoea C32D10.00 ± 22.87—
Dyspnoea C33D12.22 ± 23.46—
Dyspnoea C34D1-8.33 ± 20.72—
Dyspnoea C35D1-2.56 ± 21.35—
Dyspnoea C36D1-5.56 ± 19.25—
Dyspnoea C37D1-9.09 ± 21.56—
Dyspnoea C38D1-3.33 ± 18.92—
Dyspnoea C39D1-3.70 ± 20.03—
Dyspnoea 30 day follow up3.51 ± 16.294.27 ± 23.02
Dyspnoea 90 day follow up2.73 ± 15.272.53 ± 24.33
Insomnia Baseline20.99 ± 27.1624.79 ± 26.66
Insomnia C2D1-1.44 ± 27.47-1.54 ± 27.55
Insomnia C3D1-0.55 ± 28.14-2.54 ± 28.56
Insomnia C4D1-4.73 ± 28.47-5.13 ± 27.94
Insomnia C5D1-2.73 ± 28.06-4.44 ± 28.16
Insomnia C6D1-5.15 ± 28.40-2.51 ± 30.35
Insomnia C7D1-5.28 ± 28.34-2.91 ± 31.28
Insomnia C8D10.31 ± 29.00-4.85 ± 25.48
Insomnia C9D1-4.90 ± 29.44-4.21 ± 27.88
Insomnia C10D1-5.49 ± 29.48-0.42 ± 28.49
Insomnia C11D1-2.47 ± 29.710.94 ± 30.33
Insomnia C12D1-0.89 ± 27.39-0.58 ± 29.87
Insomnia C13D1-3.33 ± 24.321.39 ± 33.66
Insomnia C14D10.61 ± 27.59-0.76 ± 33.32
Insomnia C15D15.23 ± 23.451.85 ± 30.80
Insomnia C16D10.00 ± 25.736.45 ± 24.97
Insomnia C17D11.55 ± 25.1512.00 ± 31.74
Insomnia C18D10.00 ± 24.724.76 ± 24.23
Insomnia C19D10.00 ± 21.356.67 ± 38.39
Insomnia C20D1-0.85 ± 17.917.02 ± 23.78
Insomnia C21D10.00 ± 19.528.33 ± 30.35
Insomnia C22D1-5.38 ± 17.429.80 ± 34.89
Insomnia C23D1-3.23 ± 15.764.17 ± 34.16
Insomnia C24D10.00 ± 17.820.00 ± 24.62
Insomnia C25D1-2.38 ± 20.142.78 ± 22.29
Insomnia C26D1-2.56 ± 18.673.70 ± 20.03
Insomnia C27D1-4.00 ± 17.536.67 ± 21.08
Insomnia C28D1-1.59 ± 19.6515.15 ± 27.34
Insomnia C29D11.52 ± 21.778.33 ± 25.13
Insomnia C30D1-1.67 ± 17.01—
Insomnia C31D11.67 ± 17.01—
Insomnia C32D10.00 ± 22.87—
Insomnia C33D1-2.22 ± 19.79—
Insomnia C34D1-2.78 ± 22.29—
Insomnia C35D10.00 ± 23.57—
Insomnia C36D1-2.78 ± 17.16—
Insomnia C37D13.03 ± 23.35—
Insomnia C38D16.67 ± 34.43—
Insomnia C39D17.41 ± 22.22—
Insomnia 30 day follow up6.43 ± 30.508.55 ± 36.21
Insomnia 90 day follow up6.56 ± 22.620.42 ± 28.99
Appetite Loss Baseline26.20 ± 29.9124.66 ± 29.17
Appetite Loss C2D13.69 ± 31.97-2.61 ± 27.37
Appetite Loss C3D10.73 ± 34.86-2.71 ± 27.43
Appetite Loss C4D1-3.55 ± 34.32-5.13 ± 33.13
Appetite Loss C5D1-2.94 ± 36.24-4.44 ± 33.03
Appetite Loss C6D1-0.22 ± 34.55-2.51 ± 33.47
Appetite Loss C7D1-4.44 ± 37.41-6.88 ± 31.36
Appetite Loss C8D1-1.23 ± 31.55-6.36 ± 32.71
Appetite Loss C9D1-3.92 ± 36.72-7.12 ± 34.51
Appetite Loss C10D1-3.92 ± 31.04-10.13 ± 32.62
Appetite Loss C11D1-7.82 ± 31.30-12.21 ± 33.92
Appetite Loss C12D1-8.00 ± 31.40-11.11 ± 30.43
Appetite Loss C13D1-9.44 ± 36.36-12.50 ± 31.23
Appetite Loss C14D1-12.12 ± 31.01-11.36 ± 30.45
Appetite Loss C15D1-9.80 ± 30.03-11.11 ± 29.81
Appetite Loss C16D1-9.72 ± 32.22-8.60 ± 32.17
Appetite Loss C17D1-8.53 ± 32.61-6.67 ± 36.00
Appetite Loss C18D1-12.20 ± 32.28-9.52 ± 35.19
Appetite Loss C19D1-14.17 ± 30.09-15.00 ± 20.16
Appetite Loss C20D1-7.69 ± 33.74-15.79 ± 30.16
Appetite Loss C21D1-4.63 ± 33.00-10.00 ± 34.37
Appetite Loss C22D1-10.75 ± 32.65-17.65 ± 31.44
Appetite Loss C23D1-10.75 ± 30.29-14.58 ± 40.31
Appetite Loss C24D1-13.79 ± 28.89-16.67 ± 33.33
Appetite Loss C25D1-10.71 ± 30.16-16.67 ± 33.33
Appetite Loss C26D1-12.82 ± 35.37-14.81 ± 17.57
Appetite Loss C27D1-8.00 ± 30.85-10.00 ± 31.62
Appetite Loss C28D1-14.29 ± 32.610.00 ± 29.81
Appetite Loss C29D1-16.67 ± 28.64-11.11 ± 29.59
Appetite Loss C30D1-10.00 ± 32.62—
Appetite Loss C31D1-16.67 ± 31.53—
Appetite Loss C32D1-14.81 ± 36.55—
Appetite Loss C33D1-17.78 ± 37.52—
Appetite Loss C34D1-27.78 ± 34.33—
Appetite Loss C35D1-17.95 ± 35.00—
Appetite Loss C36D1-19.44 ± 36.12—
Appetite Loss C37D1-18.18 ± 37.61—
Appetite Loss C38D1-23.33 ± 41.72—
Appetite Loss C39D1-18.52 ± 37.68—
Appetite Loss 30 day follow up4.68 ± 38.036.41 ± 29.94
Appetite Loss 90 day follow up3.28 ± 38.830.84 ± 32.46
Constipation Baseline18.11 ± 26.0917.63 ± 27.02
Constipation C2D1-0.64 ± 24.94-2.76 ± 25.10
Constipation C3D1-2.38 ± 26.23-5.25 ± 23.58
Constipation C4D1-4.73 ± 26.30-6.90 ± 29.07
Constipation C5D1-2.73 ± 25.97-4.65 ± 26.77
Constipation C6D1-5.82 ± 26.77-4.34 ± 29.36
Constipation C7D1-7.78 ± 26.19-2.12 ± 32.32
Constipation C8D1-4.63 ± 27.14-3.03 ± 31.13
Constipation C9D1-4.25 ± 22.82-5.50 ± 29.19
Constipation C10D1-6.27 ± 26.97-7.17 ± 30.97
Constipation C11D1-4.94 ± 28.44-3.29 ± 33.88
Constipation C12D1-6.22 ± 25.52-1.17 ± 26.70
Constipation C13D1-7.78 ± 25.58-3.47 ± 33.85
Constipation C14D1-6.06 ± 25.73-2.27 ± 28.21
Constipation C15D1-4.58 ± 27.50-3.70 ± 32.64
Constipation C16D1-2.78 ± 26.48-2.15 ± 33.26
Constipation C17D1-3.88 ± 27.42-1.33 ± 26.32
Constipation C18D1-5.69 ± 25.71-6.35 ± 29.10
Constipation C19D1-5.83 ± 23.74-6.67 ± 17.44
Constipation C20D10.00 ± 31.53-7.02 ± 26.24
Constipation C21D10.00 ± 26.43-5.00 ± 31.11
Constipation C22D1-2.15 ± 32.131.96 ± 24.92
Constipation C23D1-3.23 ± 27.700.00 ± 34.43
Constipation C24D1-3.45 ± 22.445.56 ± 31.25
Constipation C25D1-3.57 ± 24.580.00 ± 24.62
Constipation C26D1-5.13 ± 26.157.41 ± 14.70
Constipation C27D1-6.67 ± 25.4610.00 ± 22.50
Constipation C28D1-4.76 ± 19.1112.12 ± 22.47
Constipation C29D10.00 ± 20.575.56 ± 19.25
Constipation C30D1-3.33 ± 21.36—
Constipation C31D10.00 ± 18.73—
Constipation C32D11.85 ± 17.98—
Constipation C33D1-6.67 ± 18.69—
Constipation C34D1-8.33 ± 15.08—
Constipation C35D1-7.69 ± 14.62—
Constipation C36D1-8.33 ± 15.08—
Constipation C37D1-12.12 ± 16.82—
Constipation C38D1-6.67 ± 14.05—
Constipation C39D1-3.70 ± 11.11—
Constipation 30 day follow up-2.34 ± 30.124.70 ± 28.29
Constipation 90 day follow up1.09 ± 27.195.91 ± 31.01
Diarrhoea Baseline8.09 ± 16.417.71 ± 15.34
Diarrhoea C2D12.56 ± 20.565.68 ± 22.98
Diarrhoea C3D12.93 ± 21.404.06 ± 20.63
Diarrhoea C4D11.38 ± 21.003.94 ± 22.07
Diarrhoea C5D11.47 ± 20.664.44 ± 20.34
Diarrhoea C6D12.91 ± 24.793.65 ± 21.49
Diarrhoea C7D11.94 ± 24.175.29 ± 19.51
Diarrhoea C8D11.23 ± 21.822.12 ± 18.77
Diarrhoea C9D11.31 ± 23.420.65 ± 19.79
Diarrhoea C10D11.18 ± 19.55-2.53 ± 17.52
Diarrhoea C11D1-3.29 ± 21.48-0.94 ± 18.66
Diarrhoea C12D1-1.33 ± 17.71-2.92 ± 20.20
Diarrhoea C13D1-3.89 ± 16.34-4.17 ± 17.70
Diarrhoea C14D1-3.03 ± 17.30-2.27 ± 20.83
Diarrhoea C15D1-1.31 ± 19.96-2.78 ± 20.12
Diarrhoea C16D1-1.39 ± 16.78-3.23 ± 13.21
Diarrhoea C17D1-0.78 ± 19.91-4.00 ± 11.06
Diarrhoea C18D1-1.63 ± 16.59-4.76 ± 19.11
Diarrhoea C19D1-2.50 ± 15.81-3.33 ± 14.91
Diarrhoea C20D1-1.71 ± 17.01-3.51 ± 15.29
Diarrhoea C21D1-0.93 ± 18.66-3.33 ± 14.91
Diarrhoea C22D10.00 ± 14.91-5.88 ± 21.20
Diarrhoea C23D11.08 ± 16.06-8.33 ± 14.91
Diarrhoea C24D12.30 ± 12.38-2.78 ± 9.62
Diarrhoea C25D10.00 ± 15.71-2.78 ± 17.16
Diarrhoea C26D10.00 ± 13.330.00 ± 16.67
Diarrhoea C27D11.33 ± 15.15-3.33 ± 18.92
Diarrhoea C28D10.00 ± 14.91-6.06 ± 20.10
Diarrhoea C29D13.03 ± 17.55-8.33 ± 25.13
Diarrhoea C30D11.67 ± 17.01—
Diarrhoea C31D1-1.67 ± 13.13—
Diarrhoea C32D15.56 ± 17.15—
Diarrhoea C33D10.00 ± 17.82—
Diarrhoea C34D1-5.56 ± 19.25—
Diarrhoea C35D12.56 ± 16.45—
Diarrhoea C36D10.00 ± 14.21—
Diarrhoea C37D10.00 ± 21.08—
Diarrhoea C38D16.67 ± 21.08—
Diarrhoea C39D13.70 ± 20.03—
Diarrhoea 30 day follow up-0.58 ± 18.361.71 ± 19.29
Diarrhoea 90 day follow up2.73 ± 20.45-1.27 ± 23.54
Financial Difficulties Baseline20.71 ± 25.9919.42 ± 25.30
Financial Difficulties C2D1-0.64 ± 25.58-0.92 ± 18.68
Financial Difficulties C3D1-0.92 ± 25.131.18 ± 22.43
Financial Difficulties C4D1-2.17 ± 23.33-1.58 ± 22.07
Financial Difficulties C5D1-0.63 ± 28.920.81 ± 19.81
Financial Difficulties C6D1-0.89 ± 27.660.00 ± 21.80
Financial Difficulties C7D10.56 ± 24.050.26 ± 24.76
Financial Difficulties C8D1-0.62 ± 26.953.33 ± 23.87
Financial Difficulties C9D12.29 ± 24.941.94 ± 21.30
Financial Difficulties C10D1-2.75 ± 27.801.27 ± 24.13
Financial Difficulties C11D10.00 ± 27.394.69 ± 22.04
Financial Difficulties C12D1-0.89 ± 30.003.51 ± 22.44
Financial Difficulties C13D1-3.33 ± 27.924.17 ± 25.38
Financial Difficulties C14D1-0.61 ± 29.040.00 ± 23.84
Financial Difficulties C15D10.00 ± 29.064.63 ± 24.11
Financial Difficulties C16D1-2.08 ± 25.186.45 ± 26.41
Financial Difficulties C17D1-2.33 ± 23.451.33 ± 20.37
Financial Difficulties C18D13.25 ± 22.124.76 ± 24.23
Financial Difficulties C19D1-2.50 ± 21.86-3.33 ± 18.42
Financial Difficulties C20D10.00 ± 24.18-1.75 ± 20.71
Financial Difficulties C21D11.85 ± 25.133.33 ± 21.36
Financial Difficulties C22D1-3.23 ± 21.703.92 ± 26.04
Financial Difficulties C23D13.23 ± 23.344.17 ± 23.96
Financial Difficulties C24D11.15 ± 22.682.78 ± 26.43
Financial Difficulties C25D10.00 ± 22.228.33 ± 20.72
Financial Difficulties C26D1-2.56 ± 20.92-7.41 ± 14.70
Financial Difficulties C27D11.33 ± 17.95-6.67 ± 14.05
Financial Difficulties C28D1-4.76 ± 21.82-3.03 ± 17.98
Financial Difficulties C29D13.03 ± 17.550.00 ± 14.21
Financial Difficulties C30D10.00 ± 24.18—
Financial Difficulties C31D10.00 ± 21.63—
Financial Difficulties C32D1-5.56 ± 17.15—
Financial Difficulties C33D1-6.67 ± 13.80—
Financial Difficulties C34D1-5.56 ± 12.97—
Financial Difficulties C35D1-2.56 ± 16.45—
Financial Difficulties C36D1-2.78 ± 17.16—
Financial Difficulties C37D1-6.06 ± 13.48—
Financial Difficulties C38D1-6.67 ± 14.05—
Financial Difficulties C39D1-3.70 ± 20.03—
Financial Difficulties 30 day follow up4.09 ± 26.039.40 ± 24.56
Financial Difficulties 90 day follow up3.28 ± 24.873.80 ± 20.66
SecondaryChange From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire

OG25 evaluated gastric \& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain \& discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was "yes or no" for STO22.Linear transformation was used; score ranged from 0 to 100;higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25.

Time frame:
Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Reported as:
Mean · Unit on a scale
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire
Unit on a scaleCAPOX+ ZolbetuximabCAPOX+ Placebo
Dysphagia Baseline12.12 ± 18.2712.59 ± 19.27
Dysphagia C2D1-0.37 ± 17.07-3.86 ± 15.69
Dysphagia C3D1-0.92 ± 15.22-4.59 ± 16.22
Dysphagia C4D1-2.68 ± 17.13-5.00 ± 17.23
Dysphagia C5D1-1.05 ± 20.30-5.66 ± 17.07
Dysphagia C6D1-1.42 ± 16.81-3.45 ± 19.00
Dysphagia C7D1-2.61 ± 16.28-5.16 ± 17.02
Dysphagia C8D1-2.88 ± 18.81-4.28 ± 17.88
Dysphagia C9D1-2.83 ± 17.67-5.93 ± 17.17
Dysphagia C10D1-3.27 ± 16.61-6.75 ± 18.70
Dysphagia C11D1-3.33 ± 16.90-5.95 ± 19.41
Dysphagia C12D1-3.70 ± 17.07-5.65 ± 16.15
Dysphagia C13D1-6.30 ± 17.64-4.40 ± 14.81
Dysphagia C14D1-4.24 ± 15.49-3.03 ± 14.25
Dysphagia C15D1-3.49 ± 14.82-1.54 ± 17.24
Dysphagia C16D1-2.31 ± 14.850.00 ± 12.83
Dysphagia C17D1-3.10 ± 13.13-1.78 ± 11.86
Dysphagia C18D1-3.25 ± 14.96-4.23 ± 10.82
Dysphagia C19D1-4.17 ± 13.48-2.78 ± 7.10
Dysphagia C20D1-4.56 ± 11.60-2.92 ± 11.01
Dysphagia C21D1-3.40 ± 15.22-3.33 ± 13.05
Dysphagia C22D1-5.38 ± 15.94-5.23 ± 9.72
Dysphagia C23D1-4.30 ± 14.54-5.56 ± 10.73
Dysphagia C24D1-4.98 ± 13.80-2.78 ± 11.73
Dysphagia C25D1-4.37 ± 12.95-3.70 ± 10.94
Dysphagia C26D1-2.99 ± 18.212.47 ± 9.26
Dysphagia C27D1-5.33 ± 12.880.00 ± 5.24
Dysphagia C28D1-4.76 ± 14.301.01 ± 5.99
Dysphagia C29D1-7.07 ± 13.951.85 ± 13.26
Dysphagia C30D1-5.00 ± 15.07—
Dysphagia C31D1-6.11 ± 13.72—
Dysphagia C32D1-7.41 ± 14.76—
Dysphagia C33D1-3.70 ± 16.08—
Dysphagia C34D1-8.33 ± 19.03—
Dysphagia C35D1-6.84 ± 19.53—
Dysphagia C36D1-9.26 ± 19.44—
Dysphagia C37D1-8.08 ± 14.13—
Dysphagia C38D1-6.67 ± 16.73—
Dysphagia C39D1-4.94 ± 12.56—
Dysphagia 30 day follow up4.48 ± 22.600.73 ± 24.63
Dysphagia 90 day follow up0.36 ± 12.33-1.83 ± 19.28
Eating Restrictions Baseline22.67 ± 25.2022.51 ± 24.22
Eating Restrictions C2D1-1.24 ± 21.39-4.55 ± 20.82
Eating Restrictions C3D1-4.12 ± 20.26-6.08 ± 20.52
Eating Restrictions C4D1-5.52 ± 21.76-8.19 ± 21.18
Eating Restrictions C5D1-5.14 ± 23.77-7.22 ± 22.12
Eating Restrictions C6D1-3.97 ± 21.24-6.03 ± 23.04
Eating Restrictions C7D1-4.69 ± 21.03-5.07 ± 22.32
Eating Restrictions C8D1-3.70 ± 21.87-6.27 ± 24.35
Eating Restrictions C9D1-3.59 ± 22.75-7.52 ± 22.25
Eating Restrictions C10D1-4.80 ± 24.03-8.54 ± 26.75
Eating Restrictions C11D1-5.83 ± 25.96-9.39 ± 27.17
Eating Restrictions C12D1-6.22 ± 27.47-9.36 ± 22.33
Eating Restrictions C13D1-9.31 ± 28.04-10.59 ± 21.59
Eating Restrictions C14D1-6.97 ± 25.45-7.39 ± 22.17
Eating Restrictions C15D1-7.03 ± 24.46-6.25 ± 21.02
Eating Restrictions C16D1-8.68 ± 22.41-6.72 ± 20.23
Eating Restrictions C17D1-7.75 ± 22.67-3.33 ± 21.52
Eating Restrictions C18D1-7.11 ± 23.68-10.32 ± 21.23
Eating Restrictions C19D1-7.92 ± 20.06-9.17 ± 14.02
Eating Restrictions C20D1-6.41 ± 22.98-9.21 ± 20.95
Eating Restrictions C21D1-5.32 ± 20.52-10.00 ± 19.61
Eating Restrictions C22D1-7.26 ± 23.93-12.25 ± 22.46
Eating Restrictions C23D1-6.18 ± 20.07-12.50 ± 19.95
Eating Restrictions C24D1-6.03 ± 21.12-6.25 ± 20.45
Eating Restrictions C25D1-5.95 ± 23.34-8.33 ± 18.46
Eating Restrictions C26D1-7.37 ± 25.31-2.78 ± 17.68
Eating Restrictions C27D1-7.67 ± 22.30-3.33 ± 13.72
Eating Restrictions C28D1-6.35 ± 24.712.27 ± 7.54
Eating Restrictions C29D1-10.23 ± 19.57-3.47 ± 19.29
Eating Restrictions C30D1-5.42 ± 22.01—
Eating Restrictions C31D1-10.42 ± 20.75—
Eating Restrictions C32D1-9.26 ± 23.90—
Eating Restrictions C33D1-7.78 ± 13.90—
Eating Restrictions C34D1-17.36 ± 25.74—
Eating Restrictions C35D1-11.54 ± 26.25—
Eating Restrictions C36D1-15.97 ± 25.24—
Eating Restrictions C37D1-12.12 ± 15.08—
Eating Restrictions C38D1-17.50 ± 21.68—
Eating Restrictions C39D1-7.41 ± 13.47—
Eating Restrictions 30 day follow up0.15 ± 27.570.88 ± 23.47
Eating Restrictions 90 day follow up-2.19 ± 22.77-0.42 ± 23.19
Reflux Baseline13.17 ± 20.2816.11 ± 22.25
Reflux C2D1-1.04 ± 20.79-4.01 ± 18.66
Reflux C3D1-0.09 ± 21.71-4.17 ± 18.36
Reflux C4D1-0.70 ± 22.80-5.82 ± 21.53
Reflux C5D1-0.84 ± 22.17-7.88 ± 19.87
Reflux C6D1-0.11 ± 22.39-7.01 ± 20.57
Reflux C7D1-1.68 ± 20.40-6.67 ± 21.48
Reflux C8D1-1.08 ± 23.04-9.17 ± 21.81
Reflux C9D1-0.82 ± 27.49-11.00 ± 20.82
Reflux C10D1-1.57 ± 23.80-10.34 ± 22.69
Reflux C11D1-3.13 ± 21.23-11.03 ± 24.23
Reflux C12D1-4.44 ± 22.48-8.48 ± 23.60
Reflux C13D1-3.33 ± 28.26-9.03 ± 24.78
Reflux C14D1-1.82 ± 22.38-8.71 ± 20.80
Reflux C15D1-3.92 ± 18.13-7.41 ± 24.70
Reflux C16D1-3.13 ± 23.23-4.84 ± 20.27
Reflux C17D1-5.81 ± 22.09-2.67 ± 21.34
Reflux C18D1-3.25 ± 23.04-3.17 ± 23.93
Reflux C19D1-2.92 ± 22.61-1.67 ± 13.13
Reflux C20D10.00 ± 20.94-4.39 ± 24.75
Reflux C21D10.46 ± 24.07-2.50 ± 27.72
Reflux C22D1-5.38 ± 17.94-1.96 ± 26.93
Reflux C23D1-4.30 ± 18.74-4.17 ± 24.72
Reflux C24D1-2.30 ± 19.78-6.94 ± 26.07
Reflux C25D1-1.19 ± 19.74-4.17 ± 25.75
Reflux C26D1-1.28 ± 16.953.70 ± 18.22
Reflux C27D1-1.33 ± 17.291.67 ± 12.30
Reflux C28D10.00 ± 17.483.03 ± 16.36
Reflux C29D1-3.03 ± 14.21-1.39 ± 8.58
Reflux C30D1-0.83 ± 13.76—
Reflux C31D1-1.67 ± 16.13—
Reflux C32D10.00 ± 18.96—
Reflux C33D1-3.33 ± 14.36—
Reflux C34D1-4.17 ± 18.97—
Reflux C35D11.28 ± 19.79—
Reflux C36D1-4.17 ± 21.47—
Reflux C37D1-4.55 ± 18.40—
Reflux C38D10.00 ± 20.79—
Reflux C39D17.41 ± 12.11—
Reflux 30 day follow up1.46 ± 26.030.44 ± 26.10
Reflux 90 day follow up2.19 ± 19.83-1.69 ± 21.28
Odynophagia Baseline15.64 ± 22.7817.29 ± 24.69
Odynophagia C2D1-2.80 ± 21.46-4.63 ± 22.20
Odynophagia C3D1-3.94 ± 19.38-6.04 ± 20.37
Odynophagia C4D1-5.22 ± 21.93-8.19 ± 21.14
Odynophagia C5D1-4.19 ± 22.58-7.58 ± 23.75
Odynophagia C6D1-2.80 ± 20.54-5.98 ± 22.96
Odynophagia C7D1-3.92 ± 19.73-5.33 ± 24.19
Odynophagia C8D1-4.32 ± 21.54-7.19 ± 23.83
Odynophagia C9D1-2.94 ± 22.30-7.93 ± 24.35
Odynophagia C10D1-5.10 ± 24.26-8.02 ± 28.35
Odynophagia C11D1-4.17 ± 25.78-9.62 ± 27.26
Odynophagia C12D1-6.67 ± 25.70-7.60 ± 22.29
Odynophagia C13D1-8.06 ± 26.66-7.99 ± 25.50
Odynophagia C14D1-7.58 ± 24.18-5.68 ± 24.10
Odynophagia C15D1-7.84 ± 23.18-3.24 ± 27.55
Odynophagia C16D1-9.37 ± 21.990.00 ± 23.17
Odynophagia C17D1-11.63 ± 21.37-2.67 ± 24.38
Odynophagia C18D1-9.76 ± 22.66-5.56 ± 23.77
Odynophagia C19D1-9.58 ± 18.45-2.50 ± 13.55
Odynophagia C20D1-7.26 ± 21.56-7.02 ± 25.65
Odynophagia C21D1-5.09 ± 18.61-7.50 ± 22.60
Odynophagia C22D1-5.91 ± 19.51-5.88 ± 27.60
Odynophagia C23D1-7.53 ± 21.01-7.29 ± 29.17
Odynophagia C24D1-6.90 ± 21.14-11.11 ± 29.59
Odynophagia C25D1-7.14 ± 18.39-9.72 ± 30.53
Odynophagia C26D1-7.69 ± 23.68-1.85 ± 13.03
Odynophagia C27D1-7.33 ± 18.05-1.67 ± 14.59
Odynophagia C28D1-9.52 ± 17.93-1.52 ± 11.68
Odynophagia C29D1-10.61 ± 18.22-1.39 ± 8.58
Odynophagia C30D1-9.17 ± 21.95—
Odynophagia C31D1-12.50 ± 19.40—
Odynophagia C32D1-11.11 ± 19.80—
Odynophagia C33D1-10.00 ± 15.17—
Odynophagia C34D1-16.67 ± 20.10—
Odynophagia C35D1-17.95 ± 20.93—
Odynophagia C36D1-18.06 ± 24.06—
Odynophagia C37D1-10.61 ± 15.41—
Odynophagia C38D1-11.67 ± 15.81—
Odynophagia C39D1-16.67 ± 14.43—
Odynophagia 30 day follow up1.75 ± 29.662.19 ± 27.53
Odynophagia 90 day follow up-0.27 ± 18.63-0.21 ± 23.19
Pain and Discomfort Baseline23.53 ± 23.8825.38 ± 25.42
Pain and Discomfort C2D1-4.25 ± 23.38-6.94 ± 24.18
Pain and Discomfort C3D1-6.59 ± 22.14-8.25 ± 21.97
Pain and Discomfort C4D1-7.33 ± 24.99-11.34 ± 24.08
Pain and Discomfort C5D1-7.44 ± 20.43-11.41 ± 26.21
Pain and Discomfort C6D1-5.82 ± 25.48-9.31 ± 27.28
Pain and Discomfort C7D1-8.54 ± 23.95-9.20 ± 24.54
Pain and Discomfort C8D1-7.10 ± 23.04-9.94 ± 25.87
Pain and Discomfort C9D1-5.07 ± 24.57-8.09 ± 26.08
Pain and Discomfort C10D1-8.24 ± 26.80-8.23 ± 28.48
Pain and Discomfort C11D1-7.71 ± 30.00-8.22 ± 28.99
Pain and Discomfort C12D1-6.44 ± 27.52-5.85 ± 25.49
Pain and Discomfort C13D1-11.39 ± 27.19-8.33 ± 29.97
Pain and Discomfort C14D1-9.39 ± 25.21-3.79 ± 27.81
Pain and Discomfort C15D1-8.82 ± 24.12-4.17 ± 29.11
Pain and Discomfort C16D1-12.15 ± 24.73-5.38 ± 28.35
Pain and Discomfort C17D1-9.69 ± 25.00-6.00 ± 28.41
Pain and Discomfort C18D1-11.79 ± 22.44-6.35 ± 28.61
Pain and Discomfort C19D1-5.83 ± 22.82-5.00 ± 17.18
Pain and Discomfort C20D1-5.56 ± 19.99-7.02 ± 26.83
Pain and Discomfort C21D1-7.41 ± 20.10-10.00 ± 23.82
Pain and Discomfort C22D1-8.06 ± 21.89-5.88 ± 31.70
Pain and Discomfort C23D1-10.22 ± 20.04-8.33 ± 29.81
Pain and Discomfort C24D1-8.62 ± 21.19-8.33 ± 29.73
Pain and Discomfort C25D1-11.90 ± 23.07-9.72 ± 32.14
Pain and Discomfort C26D1-7.69 ± 26.76-1.85 ± 28.19
Pain and Discomfort C27D1-12.00 ± 21.79-3.33 ± 15.32
Pain and Discomfort C28D1-11.90 ± 22.453.03 ± 22.13
Pain and Discomfort C29D1-12.88 ± 21.16-1.39 ± 11.14
Pain and Discomfort C30D1-10.83 ± 24.35—
Pain and Discomfort C31D1-15.00 ± 22.23—
Pain and Discomfort C32D1-17.59 ± 18.50—
Pain and Discomfort C33D1-13.33 ± 21.08—
Pain and Discomfort C34D1-20.83 ± 23.70—
Pain and Discomfort C35D1-21.79 ± 21.93—
Pain and Discomfort C36D1-19.44 ± 17.16—
Pain and Discomfort C37D1-13.64 ± 20.84—
Pain and Discomfort C38D1-13.33 ± 33.15—
Pain and Discomfort C39D1-22.22 ± 18.63—
Pain and Discomfort 30 day follow up0.88 ± 29.451.32 ± 27.99
Pain and Discomfort 90 day follow up-1.37 ± 26.75-2.95 ± 23.08
Anxiety Baseline38.96 ± 28.3142.05 ± 28.30
Anxiety C2D1-3.93 ± 25.15-7.02 ± 25.23
Anxiety C3D1-3.02 ± 24.93-6.04 ± 25.63
Anxiety C4D1-4.12 ± 24.65-7.20 ± 26.96
Anxiety C5D1-2.73 ± 26.24-6.77 ± 27.66
Anxiety C6D1-6.04 ± 23.43-8.51 ± 29.14
Anxiety C7D1-3.64 ± 23.28-8.80 ± 26.23
Anxiety C8D1-4.32 ± 25.21-8.87 ± 29.79
Anxiety C9D1-5.23 ± 25.80-6.96 ± 26.04
Anxiety C10D1-7.45 ± 28.11-11.60 ± 32.40
Anxiety C11D1-7.29 ± 28.54-8.69 ± 31.35
Anxiety C12D1-10.00 ± 29.38-8.19 ± 31.67
Anxiety C13D1-7.78 ± 30.76-6.60 ± 31.08
Anxiety C14D1-7.88 ± 28.30-5.68 ± 31.53
Anxiety C15D1-8.50 ± 28.55-6.02 ± 33.13
Anxiety C16D1-15.62 ± 27.38-3.76 ± 37.44
Anxiety C17D1-6.98 ± 24.19-6.67 ± 34.69
Anxiety C18D1-7.32 ± 28.64-10.32 ± 37.07
Anxiety C19D1-8.33 ± 25.88-2.50 ± 27.72
Anxiety C20D1-9.83 ± 24.99-8.77 ± 35.73
Anxiety C21D1-9.26 ± 29.93-11.67 ± 35.91
Anxiety C22D1-4.84 ± 27.28-7.84 ± 40.45
Anxiety C23D1-10.22 ± 26.76-10.42 ± 35.42
Anxiety C24D1-9.77 ± 28.00-9.72 ± 41.72
Anxiety C25D1-10.71 ± 24.52-11.11 ± 40.41
Anxiety C26D1-7.69 ± 25.493.70 ± 34.13
Anxiety C27D1-9.33 ± 30.086.67 ± 29.61
Anxiety C28D1-10.32 ± 31.831.52 ± 29.30
Anxiety C29D1-6.82 ± 33.201.39 ± 37.24
Anxiety C30D1-5.00 ± 26.55—
Anxiety C31D1-7.50 ± 28.34—
Anxiety C32D1-10.19 ± 32.91—
Anxiety C33D1-4.44 ± 30.52—
Anxiety C34D1-13.89 ± 27.37—
Anxiety C35D1-10.26 ± 25.04—
Anxiety C36D1-12.50 ± 26.71—
Anxiety C37D1-25.76 ± 20.23—
Anxiety C38D1-18.33 ± 22.84—
Anxiety C39D1-14.81 ± 34.81—
Anxiety 30 day follow up2.34 ± 31.253.51 ± 26.15
Anxiety 90 day follow up0.27 ± 27.47-4.22 ± 31.29
Eating in Front of Others Baseline10.70 ± 21.5310.51 ± 22.36
Eating in Front of Others C2D1-3.21 ± 18.25-3.09 ± 19.04
Eating in Front of Others C3D1-2.01 ± 18.26-3.06 ± 19.15
Eating in Front of Others C4D1-3.01 ± 16.34-7.10 ± 21.57
Eating in Front of Others C5D1-1.68 ± 15.82-5.45 ± 23.37
Eating in Front of Others C6D1-0.22 ± 15.25-4.83 ± 21.51
Eating in Front of Others C7D1-0.84 ± 18.13-4.53 ± 20.45
Eating in Front of Others C8D1-2.47 ± 18.63-5.81 ± 21.20
Eating in Front of Others C9D1-1.63 ± 21.69-5.50 ± 21.44
Eating in Front of Others C10D1-2.35 ± 23.45-6.33 ± 20.03
Eating in Front of Others C11D1-2.92 ± 19.98-4.69 ± 19.76
Eating in Front of Others C12D1-3.11 ± 20.63-4.09 ± 14.18
Eating in Front of Others C13D1-5.56 ± 21.410.00 ± 16.84
Eating in Front of Others C14D1-4.85 ± 20.71-4.55 ± 13.62
Eating in Front of Others C15D1-8.50 ± 21.95-0.93 ± 9.71
Eating in Front of Others C16D1-6.94 ± 18.14-1.08 ± 16.06
Eating in Front of Others C17D1-6.20 ± 19.590.00 ± 16.67
Eating in Front of Others C18D1-8.13 ± 19.41-3.17 ± 14.55
Eating in Front of Others C19D1-10.83 ± 21.86-1.67 ± 7.45
Eating in Front of Others C20D1-8.55 ± 19.820.00 ± 19.25
Eating in Front of Others C21D1-8.33 ± 20.12-3.33 ± 14.91
Eating in Front of Others C22D1-6.45 ± 18.09-3.92 ± 16.17
Eating in Front of Others C23D1-7.53 ± 18.68-6.25 ± 18.13
Eating in Front of Others C24D1-3.45 ± 18.57-5.56 ± 19.25
Eating in Front of Others C25D1-2.38 ± 20.14-5.56 ± 19.25
Eating in Front of Others C26D1-6.41 ± 18.90-3.70 ± 11.11
Eating in Front of Others C27D1-2.67 ± 19.050.00 ± 0.00
Eating in Front of Others C28D1-4.76 ± 26.43-3.03 ± 10.05
Eating in Front of Others C29D1-9.09 ± 21.042.78 ± 9.62
Eating in Front of Others C30D1-6.67 ± 23.20—
Eating in Front of Others C31D1-10.00 ± 21.90—
Eating in Front of Others C32D1-7.41 ± 24.40—
Eating in Front of Others C33D1-8.89 ± 23.46—
Eating in Front of Others C34D1-16.67 ± 22.47—
Eating in Front of Others C35D1-5.13 ± 22.96—
Eating in Front of Others C36D1-11.11 ± 21.71—
Eating in Front of Others C37D1-12.12 ± 22.47—
Eating in Front of Others C38D1-16.67 ± 23.57—
Eating in Front of Others C39D1-7.41 ± 14.70—
Eating in Front of Others 30 day follow up2.92 ± 23.811.75 ± 24.28
Eating in Front of Others 90 day follow up3.28 ± 18.962.53 ± 16.69
Dry Mouth Baseline19.20 ± 24.7416.87 ± 23.79
Dry Mouth C2D1-0.32 ± 23.402.16 ± 23.30
Dry Mouth C3D1-0.55 ± 23.894.93 ± 26.44
Dry Mouth C4D1-2.01 ± 25.084.34 ± 28.30
Dry Mouth C5D1-1.05 ± 26.891.41 ± 27.88
Dry Mouth C6D10.89 ± 27.933.91 ± 27.64
Dry Mouth C7D1-0.28 ± 27.620.53 ± 28.08
Dry Mouth C8D1-1.85 ± 25.713.98 ± 29.65
Dry Mouth C9D10.00 ± 28.922.27 ± 28.49
Dry Mouth C10D1-5.88 ± 28.72-2.11 ± 27.39
Dry Mouth C11D1-4.58 ± 26.38-2.35 ± 26.02
Dry Mouth C12D1-5.78 ± 26.491.17 ± 25.17
Dry Mouth C13D1-5.00 ± 26.63-2.08 ± 27.85
Dry Mouth C14D1-7.27 ± 26.21-2.27 ± 26.31
Dry Mouth C15D1-5.88 ± 24.680.00 ± 21.08
Dry Mouth C16D1-7.64 ± 25.021.08 ± 16.06
Dry Mouth C17D1-6.20 ± 19.594.00 ± 17.53
Dry Mouth C18D1-5.69 ± 19.584.76 ± 15.94
Dry Mouth C19D1-9.17 ± 25.023.33 ± 14.91
Dry Mouth C20D1-8.55 ± 21.243.51 ± 24.58
Dry Mouth C21D1-5.56 ± 24.563.33 ± 18.42
Dry Mouth C22D1-9.68 ± 23.087.84 ± 18.74
Dry Mouth C23D1-7.53 ± 23.902.08 ± 14.75
Dry Mouth C24D1-6.90 ± 24.205.56 ± 27.83
Dry Mouth C25D1-10.71 ± 22.322.78 ± 17.16
Dry Mouth C26D1-8.97 ± 27.580.00 ± 16.67
Dry Mouth C27D1-6.67 ± 21.523.33 ± 18.92
Dry Mouth C28D1-4.76 ± 26.430.00 ± 14.91
Dry Mouth C29D1-6.06 ± 28.43-2.78 ± 17.16
Dry Mouth C30D1-5.00 ± 24.84—
Dry Mouth C31D1-8.33 ± 28.36—
Dry Mouth C32D1-11.11 ± 30.25—
Dry Mouth C33D1-15.56 ± 21.33—
Dry Mouth C34D1-22.22 ± 21.71—
Dry Mouth C35D1-17.95 ± 25.88—
Dry Mouth C36D1-16.67 ± 17.41—
Dry Mouth C37D1-18.18 ± 31.14—
Dry Mouth C38D1-20.00 ± 32.20—
Dry Mouth C39D1-22.22 ± 33.33—
Dry Mouth 30 day follow up-4.68 ± 26.315.70 ± 26.88
Dry Mouth 90 day follow up3.83 ± 25.166.75 ± 28.43
Trouble with Taste Baseline9.47 ± 21.587.47 ± 18.50
Trouble with Taste C2D13.85 ± 22.852.47 ± 20.69
Trouble with Taste C3D17.33 ± 25.415.27 ± 20.55
Trouble with Taste C4D15.62 ± 24.245.52 ± 24.31
Trouble with Taste C5D18.18 ± 26.718.08 ± 25.01
Trouble with Taste C6D112.30 ± 27.7711.72 ± 27.65
Trouble with Taste C7D110.92 ± 28.829.33 ± 25.96
Trouble with Taste C8D110.49 ± 25.2310.40 ± 28.58
Trouble with Taste C9D18.17 ± 29.836.47 ± 25.16
Trouble with Taste C10D17.06 ± 29.592.95 ± 26.25
Trouble with Taste C11D12.92 ± 27.144.23 ± 26.39
Trouble with Taste C12D12.22 ± 26.470.00 ± 21.82
Trouble with Taste C13D10.56 ± 32.183.47 ± 19.74
Trouble with Taste C14D11.82 ± 25.991.52 ± 22.68
Trouble with Taste C15D10.00 ± 27.491.85 ± 23.83
Trouble with Taste C16D11.39 ± 25.693.23 ± 15.76
Trouble with Taste C17D11.55 ± 24.078.00 ± 14.53
Trouble with Taste C18D10.81 ± 24.144.76 ± 11.95
Trouble with Taste C19D10.83 ± 21.991.67 ± 7.45
Trouble with Taste C20D12.56 ± 22.147.02 ± 13.96
Trouble with Taste C21D1-0.93 ± 24.5410.00 ± 15.67
Trouble with Taste C22D1-1.08 ± 26.505.88 ± 13.10
Trouble with Taste C23D12.15 ± 24.248.33 ± 19.25
Trouble with Taste C24D10.00 ± 19.922.78 ± 9.62
Trouble with Taste C25D12.38 ± 20.145.56 ± 12.97
Trouble with Taste C26D1-1.28 ± 19.9611.11 ± 16.67
Trouble with Taste C27D10.00 ± 19.253.33 ± 10.54
Trouble with Taste C28D13.17 ± 23.343.03 ± 10.05
Trouble with Taste C29D14.55 ± 21.328.33 ± 15.08
Trouble with Taste C30D11.67 ± 20.16—
Trouble with Taste C31D11.67 ± 22.88—
Trouble with Taste C32D10.00 ± 22.87—
Trouble with Taste C33D1-2.22 ± 23.46—
Trouble with Taste C34D1-8.33 ± 20.72—
Trouble with Taste C35D1-2.56 ± 21.35—
Trouble with Taste C36D1-2.78 ± 22.29—
Trouble with Taste C37D1-3.03 ± 27.71—
Trouble with Taste C38D1-3.33 ± 29.19—
Trouble with Taste C39D10.00 ± 16.67—
Trouble with Taste 30 day follow up4.09 ± 23.639.21 ± 29.11
Trouble with Taste 90 day follow up7.65 ± 25.387.59 ± 22.61
Body Image Baseline17.97 ± 25.7519.64 ± 23.99
Body Image C2D1-0.80 ± 22.80-2.31 ± 22.04
Body Image C3D11.47 ± 24.48-1.53 ± 23.94
Body Image C4D11.00 ± 26.32-0.99 ± 22.25
Body Image C5D12.52 ± 28.450.61 ± 22.83
Body Image C6D13.58 ± 24.55-1.38 ± 26.61
Body Image C7D10.28 ± 25.85-0.80 ± 25.56
Body Image C8D12.78 ± 26.620.00 ± 24.43
Body Image C9D11.31 ± 24.34-0.97 ± 24.01
Body Image C10D1-1.57 ± 29.95-0.42 ± 26.95
Body Image C11D1-5.00 ± 26.570.94 ± 26.41
Body Image C12D1-3.56 ± 29.29-2.34 ± 22.59
Body Image C13D1-7.22 ± 30.120.00 ± 26.63
Body Image C14D1-6.06 ± 27.29-2.27 ± 25.31
Body Image C15D1-5.88 ± 28.83-0.93 ± 28.16
Body Image C16D1-7.64 ± 27.711.08 ± 26.50
Body Image C17D1-6.20 ± 27.46-2.67 ± 23.41
Body Image C18D1-8.13 ± 25.58-4.76 ± 26.43
Body Image C19D1-6.67 ± 24.11-1.67 ± 13.13
Body Image C20D1-3.42 ± 23.93-3.51 ± 29.18
Body Image C21D1-9.26 ± 20.49-8.33 ± 23.88
Body Image C22D1-5.38 ± 24.49-3.92 ± 30.92
Body Image C23D1-8.60 ± 19.18-8.33 ± 28.54
Body Image C24D1-8.05 ± 17.03-5.56 ± 34.33
Body Image C25D1-8.33 ± 23.35-2.78 ± 33.21
Body Image C26D1-6.41 ± 23.133.70 ± 11.11
Body Image C27D1-6.67 ± 19.253.33 ± 10.54
Body Image C28D1-9.52 ± 21.466.06 ± 13.48
Body Image C29D1-9.09 ± 25.585.56 ± 12.97
Body Image C30D1-3.33 ± 21.36—
Body Image C31D1-10.00 ± 21.90—
Body Image C32D1-11.11 ± 22.87—
Body Image C33D1-15.56 ± 24.77—
Body Image C34D1-13.89 ± 17.16—
Body Image C35D1-10.26 ± 16.01—
Body Image C36D1-11.11 ± 16.41—
Body Image C37D1-15.15 ± 17.41—
Body Image C38D1-16.67 ± 17.57—
Body Image C39D1-11.11 ± 16.67—
Body Image 30 day follow up3.51 ± 30.005.26 ± 26.70
Body Image 90 day follow up7.10 ± 20.296.75 ± 29.42
Trouble Swallowing Saliva Baseline3.84 ± 12.645.26 ± 15.52
Trouble Swallowing Saliva C2D10.48 ± 13.70-1.85 ± 14.62
Trouble Swallowing Saliva C3D10.00 ± 13.57-1.19 ± 15.97
Trouble Swallowing Saliva C4D10.20 ± 16.20-0.59 ± 16.05
Trouble Swallowing Saliva C5D10.21 ± 15.23-2.63 ± 16.04
Trouble Swallowing Saliva C6D12.91 ± 18.960.00 ± 18.84
Trouble Swallowing Saliva C7D11.40 ± 18.61-1.33 ± 18.16
Trouble Swallowing Saliva C8D1-0.62 ± 15.77-3.06 ± 16.06
Trouble Swallowing Saliva C9D10.65 ± 15.54-3.56 ± 19.75
Trouble Swallowing Saliva C10D10.78 ± 17.04-4.22 ± 20.23
Trouble Swallowing Saliva C11D1-0.42 ± 13.52-4.69 ± 18.94
Trouble Swallowing Saliva C12D10.00 ± 10.96-4.68 ± 19.35
Trouble Swallowing Saliva C13D10.00 ± 12.27-2.78 ± 19.25
Trouble Swallowing Saliva C14D1-1.21 ± 11.04-3.79 ± 25.13
Trouble Swallowing Saliva C15D1-1.96 ± 14.00-6.48 ± 23.66
Trouble Swallowing Saliva C16D10.00 ± 16.84-4.30 ± 20.62
Trouble Swallowing Saliva C17D1-2.33 ± 13.40-6.67 ± 19.25
Trouble Swallowing Saliva C18D1-2.44 ± 13.72-6.35 ± 22.65
Trouble Swallowing Saliva C19D1-0.83 ± 15.99-5.00 ± 16.31
Trouble Swallowing Saliva C20D1-3.42 ± 16.75-7.02 ± 23.78
Trouble Swallowing Saliva C21D10.00 ± 17.82-5.00 ± 27.09
Trouble Swallowing Saliva C22D10.00 ± 12.17-5.88 ± 24.25
Trouble Swallowing Saliva C23D10.00 ± 12.17-10.42 ± 23.47
Trouble Swallowing Saliva C24D10.00 ± 12.60-8.33 ± 20.72
Trouble Swallowing Saliva C25D11.19 ± 14.29-13.89 ± 26.43
Trouble Swallowing Saliva C26D1-1.28 ± 11.47-11.11 ± 23.57
Trouble Swallowing Saliva C27D10.00 ± 13.61-10.00 ± 22.50
Trouble Swallowing Saliva C28D10.00 ± 10.54-9.09 ± 21.56
Trouble Swallowing Saliva C29D11.52 ± 12.50-8.33 ± 20.72
Trouble Swallowing Saliva C30D10.00 ± 10.81—
Trouble Swallowing Saliva C31D10.00 ± 10.81—
Trouble Swallowing Saliva C32D1-1.85 ± 7.86—
Trouble Swallowing Saliva C33D1-2.22 ± 8.61—
Trouble Swallowing Saliva C34D10.00 ± 14.21—
Trouble Swallowing Saliva C35D10.00 ± 13.61—
Trouble Swallowing Saliva C36D1-2.78 ± 9.62—
Trouble Swallowing Saliva C37D10.00 ± 14.91—
Trouble Swallowing Saliva C38D10.00 ± 15.71—
Trouble Swallowing Saliva C39D10.00 ± 0.00—
Trouble Swallowing Saliva 30 day follow up1.75 ± 20.34-1.75 ± 17.12
Trouble Swallowing Saliva 90 day follow up1.64 ± 16.58-2.95 ± 21.48
Choked When Swallowing Baseline5.35 ± 14.016.64 ± 17.00
Choked When Swallowing C2D1-1.60 ± 13.81-1.54 ± 15.00
Choked When Swallowing C3D1-1.10 ± 12.09-1.87 ± 17.92
Choked When Swallowing C4D1-2.01 ± 14.07-1.38 ± 16.41
Choked When Swallowing C5D1-1.68 ± 15.82-2.42 ± 17.09
Choked When Swallowing C6D1-1.12 ± 15.70-1.84 ± 18.33
Choked When Swallowing C7D10.56 ± 19.40-2.93 ± 19.41
Choked When Swallowing C8D1-0.31 ± 14.76-3.67 ± 18.89
Choked When Swallowing C9D1-0.65 ± 14.82-2.27 ± 19.95
Choked When Swallowing C10D1-1.96 ± 14.87-2.95 ± 19.39
Choked When Swallowing C11D1-0.83 ± 14.98-2.82 ± 18.47
Choked When Swallowing C12D1-2.22 ± 14.84-1.75 ± 15.96
Choked When Swallowing C13D1-3.33 ± 14.65-4.17 ± 18.99
Choked When Swallowing C14D1-3.03 ± 11.61-1.52 ± 21.51
Choked When Swallowing C15D1-3.92 ± 12.730.93 ± 24.54
Choked When Swallowing C16D1-2.08 ± 12.691.08 ± 21.92
Choked When Swallowing C17D1-1.55 ± 7.10-4.00 ± 22.19
Choked When Swallowing C18D1-0.81 ± 11.76-3.17 ± 17.97
Choked When Swallowing C19D1-1.67 ± 10.54-1.67 ± 7.45
Choked When Swallowing C20D1-2.56 ± 11.81-3.51 ± 18.90
Choked When Swallowing C21D1-1.85 ± 15.83-5.00 ± 16.31
Choked When Swallowing C22D1-2.15 ± 11.97-3.92 ± 20.01
Choked When Swallowing C23D1-2.15 ± 14.75-4.17 ± 20.64
Choked When Swallowing C24D1-1.15 ± 14.04-5.56 ± 19.25
Choked When Swallowing C25D1-3.57 ± 13.88-5.56 ± 19.25
Choked When Swallowing C26D1-2.56 ± 13.070.00 ± 0.00
Choked When Swallowing C27D1-1.33 ± 17.950.00 ± 0.00
Choked When Swallowing C28D10.00 ± 18.260.00 ± 0.00
Choked When Swallowing C29D11.52 ± 16.19-2.78 ± 9.62
Choked When Swallowing C30D13.33 ± 18.42—
Choked When Swallowing C31D11.67 ± 17.01—
Choked When Swallowing C32D10.00 ± 19.80—
Choked When Swallowing C33D1-2.22 ± 15.26—
Choked When Swallowing C34D10.00 ± 20.10—
Choked When Swallowing C35D12.56 ± 21.35—
Choked When Swallowing C36D12.78 ± 17.16—
Choked When Swallowing C37D1-3.03 ± 17.98—
Choked When Swallowing C38D1-3.33 ± 18.92—
Choked When Swallowing C39D10.00 ± 16.67—
Choked When Swallowing 30 day follow up4.09 ± 21.89-3.07 ± 19.00
Choked When Swallowing 90 day follow up0.00 ± 14.91-1.69 ± 21.94
Trouble with Coughing Baseline10.56 ± 17.499.82 ± 19.49
Trouble with Coughing C2D1-0.48 ± 16.86-0.77 ± 18.59
Trouble with Coughing C3D1-2.01 ± 17.92-0.68 ± 19.08
Trouble with Coughing C4D1-1.61 ± 19.00-0.99 ± 20.39
Trouble with Coughing C5D10.21 ± 19.30-2.63 ± 18.03
Trouble with Coughing C6D10.22 ± 23.41-1.38 ± 16.61
Trouble with Coughing C7D1-2.24 ± 19.76-1.87 ± 19.54
Trouble with Coughing C8D1-0.31 ± 17.94-1.22 ± 20.75
Trouble with Coughing C9D1-3.92 ± 20.06-2.91 ± 21.44
Trouble with Coughing C10D1-3.53 ± 22.43-2.11 ± 25.79
Trouble with Coughing C11D1-4.17 ± 22.73-4.23 ± 25.15
Trouble with Coughing C12D1-2.67 ± 23.09-8.19 ± 22.96
Trouble with Coughing C13D1-5.00 ± 25.91-6.94 ± 22.76
Trouble with Coughing C14D1-6.06 ± 15.83-6.82 ± 23.38
Trouble with Coughing C15D1-7.19 ± 20.35-7.41 ± 21.25
Trouble with Coughing C16D1-4.17 ± 23.44-8.60 ± 19.18
Trouble with Coughing C17D1-7.75 ± 22.811.33 ± 17.95
Trouble with Coughing C18D1-6.50 ± 21.37-4.76 ± 19.11
Trouble with Coughing C19D1-5.00 ± 17.78-1.67 ± 7.45
Trouble with Coughing C20D1-3.42 ± 19.93-5.26 ± 22.94
Trouble with Coughing C21D1-4.63 ± 19.76-1.67 ± 20.16
Trouble with Coughing C22D1-5.38 ± 17.42-5.88 ± 21.20
Trouble with Coughing C23D1-4.30 ± 18.74-6.25 ± 21.84
Trouble with Coughing C24D1-3.45 ± 18.57-5.56 ± 23.92
Trouble with Coughing C25D1-2.38 ± 17.98-5.56 ± 19.25
Trouble with Coughing C26D1-1.28 ± 17.59-3.70 ± 20.03
Trouble with Coughing C27D1-4.00 ± 17.53-3.33 ± 18.92
Trouble with Coughing C28D1-1.59 ± 12.810.00 ± 21.08
Trouble with Coughing C29D13.03 ± 22.79-2.78 ± 17.16
Trouble with Coughing C30D11.67 ± 17.01—
Trouble with Coughing C31D13.33 ± 21.36—
Trouble with Coughing C32D13.70 ± 19.43—
Trouble with Coughing C33D1-4.44 ± 11.73—
Trouble with Coughing C34D10.00 ± 14.21—
Trouble with Coughing C35D1-2.56 ± 16.45—
Trouble with Coughing C36D1-5.56 ± 12.97—
Trouble with Coughing C37D1-6.06 ± 13.48—
Trouble with Coughing C38D10.00 ± 15.71—
Trouble with Coughing C39D13.70 ± 11.11—
Trouble with Coughing 30 day follow up1.17 ± 21.791.32 ± 28.51
Trouble with Coughing 90 day follow up2.19 ± 15.951.27 ± 25.29
Trouble Talking Baseline3.84 ± 14.343.60 ± 12.40
Trouble Talking C2D10.96 ± 13.07-0.31 ± 9.64
Trouble Talking C3D1-0.18 ± 11.35-1.02 ± 11.65
Trouble Talking C4D1-0.40 ± 12.710.99 ± 14.28
Trouble Talking C5D11.68 ± 11.74-0.81 ± 11.01
Trouble Talking C6D10.67 ± 13.680.46 ± 11.78
Trouble Talking C7D10.84 ± 15.32-0.53 ± 11.19
Trouble Talking C8D10.93 ± 12.45-1.22 ± 13.55
Trouble Talking C9D10.65 ± 15.540.32 ± 13.60
Trouble Talking C10D10.39 ± 14.08-1.27 ± 15.51
Trouble Talking C11D10.42 ± 12.43-1.41 ± 13.14
Trouble Talking C12D1-1.33 ± 11.550.58 ± 7.69
Trouble Talking C13D1-2.78 ± 12.71-1.39 ± 15.31
Trouble Talking C14D1-3.03 ± 11.610.00 ± 16.07
Trouble Talking C15D1-3.27 ± 13.75-1.85 ± 13.67
Trouble Talking C16D10.00 ± 16.84-1.08 ± 16.06
Trouble Talking C17D1-4.65 ± 13.772.67 ± 13.33
Trouble Talking C18D1-3.25 ± 12.483.17 ± 14.55
Trouble Talking C19D10.00 ± 15.101.67 ± 7.45
Trouble Talking C20D1-2.56 ± 14.071.75 ± 13.49
Trouble Talking C21D1-0.93 ± 18.663.33 ± 18.42
Trouble Talking C22D1-3.23 ± 13.210.00 ± 20.41
Trouble Talking C23D1-1.08 ± 13.56-2.08 ± 19.12
Trouble Talking C24D1-2.30 ± 12.380.00 ± 24.62
Trouble Talking C25D1-1.19 ± 14.292.78 ± 17.16
Trouble Talking C26D1-1.28 ± 14.853.70 ± 11.11
Trouble Talking C27D1-2.67 ± 13.333.33 ± 10.54
Trouble Talking C28D1-3.17 ± 14.553.03 ± 10.05
Trouble Talking C29D1-1.52 ± 16.192.78 ± 9.62
Trouble Talking C30D1-1.67 ± 17.01—
Trouble Talking C31D10.00 ± 18.73—
Trouble Talking C32D1-1.85 ± 17.98—
Trouble Talking C33D1-4.44 ± 17.21—
Trouble Talking C34D1-5.56 ± 19.25—
Trouble Talking C35D1-5.13 ± 18.49—
Trouble Talking C36D1-5.56 ± 19.25—
Trouble Talking C37D1-6.06 ± 20.10—
Trouble Talking C38D1-6.67 ± 21.08—
Trouble Talking C39D10.00 ± 0.00—
Trouble Talking 30 day follow up4.68 ± 18.302.19 ± 15.72
Trouble Talking 90 day follow up3.83 ± 10.713.38 ± 20.39
Weight Loss Baseline23.05 ± 27.4324.07 ± 28.25
Weight Loss C2D10.16 ± 23.280.46 ± 26.99
Weight Loss C3D10.92 ± 26.781.02 ± 27.20
Weight Loss C4D10.00 ± 28.19-1.18 ± 25.69
Weight Loss C5D12.52 ± 32.38-2.42 ± 26.43
Weight Loss C6D1-0.45 ± 25.99-5.29 ± 29.05
Weight Loss C7D1-2.52 ± 27.84-3.47 ± 28.02
Weight Loss C8D1-2.47 ± 26.46-3.67 ± 29.17
Weight Loss C9D1-5.88 ± 29.45-7.12 ± 29.76
Weight Loss C10D1-7.06 ± 32.57-5.91 ± 28.12
Weight Loss C11D1-9.58 ± 30.56-8.45 ± 25.65
Weight Loss C12D1-10.22 ± 30.50-10.53 ± 24.53
Weight Loss C13D1-11.67 ± 28.67-10.42 ± 25.87
Weight Loss C14D1-13.94 ± 26.21-6.82 ± 23.38
Weight Loss C15D1-12.42 ± 26.63-8.33 ± 30.21
Weight Loss C16D1-15.97 ± 22.79-8.60 ± 22.72
Weight Loss C17D1-14.73 ± 19.66-13.33 ± 21.52
Weight Loss C18D1-11.38 ± 25.40-14.29 ± 27.02
Weight Loss C19D1-16.67 ± 22.65-11.67 ± 16.31
Weight Loss C20D1-10.26 ± 21.84-12.28 ± 25.36
Weight Loss C21D1-12.96 ± 22.93-16.67 ± 25.36
Weight Loss C22D1-12.90 ± 23.85-17.65 ± 26.66
Weight Loss C23D1-10.75 ± 19.98-22.92 ± 29.11
Weight Loss C24D1-10.34 ± 26.88-13.89 ± 30.01
Weight Loss C25D1-10.71 ± 20.39-11.11 ± 25.95
Weight Loss C26D1-16.67 ± 25.39-11.11 ± 16.67
Weight Loss C27D1-12.00 ± 21.26-13.33 ± 23.31
Weight Loss C28D1-14.29 ± 22.54-6.06 ± 13.48
Weight Loss C29D1-13.64 ± 19.68-8.33 ± 15.08
Weight Loss C30D1-15.00 ± 20.16—
Weight Loss C31D1-11.67 ± 19.57—
Weight Loss C32D1-20.37 ± 20.26—
Weight Loss C33D1-15.56 ± 24.77—
Weight Loss C34D1-16.67 ± 26.59—
Weight Loss C35D1-15.38 ± 22.01—
Weight Loss C36D1-13.89 ± 22.29—
Weight Loss C37D1-18.18 ± 27.34—
Weight Loss C38D1-20.00 ± 23.31—
Weight Loss C39D1-14.81 ± 24.22—
Weight Loss 30 day follow up-1.75 ± 30.493.95 ± 27.74
Weight Loss 90 day follow up-1.64 ± 24.672.95 ± 30.75
Hair Loss Baseline12.09 ± 20.8012.55 ± 23.56
Hair Loss C2D1-2.26 ± 18.43-1.67 ± 15.56
Hair Loss C3D1-3.09 ± 19.71-4.76 ± 23.57
Hair Loss C4D1-0.63 ± 24.010.00 ± 15.71
Hair Loss C5D1-3.03 ± 20.10-0.81 ± 18.99
Hair Loss C6D12.96 ± 23.38-4.63 ± 21.31
Hair Loss C7D1-3.33 ± 22.06-4.60 ± 17.19
Hair Loss C8D1-5.71 ± 27.40-8.97 ± 20.13
Hair Loss C9D1-2.22 ± 26.16-9.52 ± 26.13
Hair Loss C10D1-1.67 ± 25.31-8.33 ± 28.54
Hair Loss C11D1-1.67 ± 27.523.03 ± 17.98
Hair Loss C12D1-4.55 ± 25.810.00 ± 20.10
Hair Loss C13D1-5.26 ± 29.94-6.67 ± 21.08
Hair Loss C14D1-11.11 ± 29.594.76 ± 12.60
Hair Loss C15D16.06 ± 25.03-4.76 ± 12.60
Hair Loss C16D1-2.56 ± 16.45-6.67 ± 14.91
Hair Loss C17D10.00 ± 21.080.00 ± 0.00
Hair Loss C18D10.00 ± 22.22—
Hair Loss C19D10.00 ± 17.82-13.33 ± 18.26
Hair Loss C20D1-3.33 ± 18.920.00 ± 0.00
Hair Loss C21D1-3.33 ± 18.92—
Hair Loss C22D10.00 ± 17.82—
Hair Loss C23D10.00 ± 21.08—
Hair Loss C24D1-4.76 ± 23.00—
Hair Loss C25D10.00 ± 21.08—
Hair Loss 30 day follow up8.33 ± 23.572.38 ± 30.56
Hair Loss 90 day follow up23.53 ± 40.4215.15 ± 26.68
Belching Baseline12.14 ± 18.6214.11 ± 21.01
Belching C2D1-1.52 ± 15.68-3.09 ± 14.93
Belching C3D10.92 ± 17.84-1.87 ± 16.94
Belching C4D10.20 ± 16.51-3.16 ± 18.81
Belching C5D11.68 ± 17.81-5.35 ± 18.59
Belching C6D10.00 ± 16.67-4.02 ± 20.53
Belching C7D10.28 ± 17.36-5.07 ± 20.66
Belching C8D11.54 ± 20.95-5.05 ± 21.46
Belching C9D11.31 ± 18.27-9.39 ± 20.44
Belching C10D10.39 ± 18.54-7.38 ± 19.93
Belching C11D1-2.08 ± 17.26-9.62 ± 21.21
Belching C12D1-1.78 ± 16.11-7.60 ± 18.65
Belching C13D1-0.28 ± 20.00-7.64 ± 22.27
Belching C14D10.00 ± 17.27-6.06 ± 20.99
Belching C15D1-1.31 ± 16.61-5.56 ± 19.92
Belching C16D1-2.78 ± 18.30-5.91 ± 22.17
Belching C17D1-2.71 ± 18.87-5.33 ± 22.42
Belching C18D1-2.03 ± 17.16-3.17 ± 27.19
Belching C19D10.42 ± 15.33-2.50 ± 11.18
Belching C20D11.28 ± 18.09-7.02 ± 21.74
Belching C21D1-0.93 ± 14.33-5.00 ± 23.63
Belching C22D1-0.54 ± 17.99-4.90 ± 28.73
Belching C23D1-3.23 ± 16.34-9.38 ± 23.55
Belching C24D10.00 ± 16.67-5.56 ± 32.05
Belching C25D10.60 ± 17.26-8.33 ± 31.38
Belching C26D11.92 ± 17.213.70 ± 20.03
Belching C27D10.00 ± 15.210.00 ± 13.61
Belching C28D13.97 ± 13.851.52 ± 13.85
Belching C29D10.00 ± 15.43-1.39 ± 11.14
Belching C30D10.83 ± 14.78—
Belching C31D12.50 ± 16.47—
Belching C32D14.63 ± 17.90—
Belching C33D1-1.11 ± 14.73—
Belching C34D10.00 ± 12.31—
Belching C35D13.85 ± 20.59—
Belching C36D11.39 ± 19.41—
Belching C37D16.06 ± 11.24—
Belching C38D11.67 ± 16.57—
Belching C39D13.70 ± 7.35—
Belching 30 day follow up3.22 ± 21.230.66 ± 19.52
Belching 90 day follow up-0.55 ± 15.20-1.90 ± 17.50
SecondaryChange From Baseline in HRQoL Measured by Global Pain (GP)

The GP instrument is a single assessment of overall pain and participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain. Low pain scores are considered a better outcome than a high pain score.

Time frame:
Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Reported as:
Mean · Unit on a scale
Change From Baseline in HRQoL Measured by Global Pain (GP)
Unit on a scaleCAPOX+ ZolbetuximabCAPOX+ Placebo
Baseline2.45 ± 2.492.64 ± 2.55
C2D1-0.60 ± 2.61-0.63 ± 2.59
C3D1-0.74 ± 2.30-0.82 ± 2.33
C4D1-0.63 ± 2.58-0.91 ± 2.68
C5D1-0.37 ± 2.89-0.79 ± 2.84
C6D1-0.51 ± 2.61-0.57 ± 3.00
C7D1-0.61 ± 2.65-0.38 ± 2.74
C8D1-0.59 ± 2.45-0.36 ± 2.48
C9D1-0.65 ± 2.62-0.36 ± 2.63
C10D1-0.71 ± 2.67-0.71 ± 2.65
C11D1-0.40 ± 2.96-0.61 ± 2.55
C12D10.08 ± 2.91-0.53 ± 2.41
C13D10.05 ± 3.40-0.63 ± 2.44
C14D1-0.95 ± 2.63-0.34 ± 2.12
C15D1-0.80 ± 2.62-0.44 ± 1.81
C16D1-0.19 ± 3.070.10 ± 2.23
C17D1-0.74 ± 2.46-0.20 ± 1.32
C18D10.17 ± 3.26-0.48 ± 1.29
C19D1-0.20 ± 2.53-0.25 ± 0.97
C20D10.05 ± 2.720.21 ± 2.90
C21D1-0.06 ± 2.860.50 ± 2.96
C22D10.00 ± 2.890.00 ± 2.92
C23D1-0.19 ± 2.170.69 ± 3.22
C24D1-0.45 ± 3.41-0.33 ± 1.72
C25D1-0.86 ± 2.170.17 ± 3.21
C26D1-0.58 ± 2.530.22 ± 1.86
C27D1-1.08 ± 2.250.80 ± 3.29
C28D10.05 ± 2.890.18 ± 1.33
C29D1-0.14 ± 2.25-0.17 ± 0.72
C30D1-0.45 ± 2.11—
C31D1-0.45 ± 2.24—
C32D1-0.50 ± 2.71—
C33D10.07 ± 3.24—
C34D1-0.67 ± 3.20—
C35D1-0.69 ± 2.84—
C36D1-1.42 ± 1.56—
C37D10.18 ± 3.06—
C38D10.00 ± 3.53—
C39D1-0.89 ± 1.27—
30 day follow up0.74 ± 3.340.56 ± 2.63
90 day follow up0.08 ± 3.340.62 ± 2.81
SecondaryChange From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire

EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status. It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

Time frame:
Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
Reported as:
Mean · Unit on a scale
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
Unit on a scaleCAPOX+ ZolbetuximabCAPOX+ Placebo
Mobility Baseline1.33 ± 0.671.33 ± 0.67
Mobility C2D10.02 ± 0.600.06 ± 0.67
Mobility C3D1-0.01 ± 0.610.05 ± 0.65
Mobility C4D1-0.01 ± 0.620.02 ± 0.76
Mobility C5D10.05 ± 0.650.00 ± 0.78
Mobility C6D10.04 ± 0.770.03 ± 0.86
Mobility C7D10.02 ± 0.720.02 ± 0.70
Mobility C8D10.20 ± 0.810.05 ± 0.78
Mobility C9D10.18 ± 0.780.06 ± 0.75
Mobility C10D10.08 ± 0.740.13 ± 0.74
Mobility C11D10.12 ± 0.680.15 ± 0.87
Mobility C12D10.08 ± 0.650.02 ± 0.66
Mobility C13D10.08 ± 0.740.10 ± 0.85
Mobility C14D1-0.05 ± 0.640.11 ± 0.53
Mobility C15D1-0.04 ± 0.690.03 ± 0.55
Mobility C16D10.02 ± 0.640.06 ± 0.56
Mobility C17D10.00 ± 0.720.08 ± 0.48
Mobility C18D10.07 ± 0.520.09 ± 0.43
Mobility C19D10.03 ± 0.530.00 ± 0.32
Mobility C20D10.10 ± 0.550.10 ± 0.55
Mobility C21D10.03 ± 0.51-0.14 ± 0.48
Mobility C22D10.03 ± 0.55-0.11 ± 0.58
Mobility C23D10.00 ± 0.58-0.12 ± 0.60
Mobility C24D10.07 ± 0.53-0.15 ± 0.69
Mobility C25D10.21 ± 0.63-0.08 ± 0.76
Mobility C26D10.15 ± 0.540.10 ± 0.32
Mobility C27D10.08 ± 0.76-0.09 ± 0.30
Mobility C28D10.24 ± 0.890.09 ± 0.30
Mobility C29D10.05 ± 0.65-0.08 ± 0.51
Mobility C30D10.10 ± 0.64—
Mobility C31D10.00 ± 0.56—
Mobility C32D10.06 ± 0.54—
Mobility C33D10.00 ± 0.76—
Mobility C34D1-0.08 ± 0.79—
Mobility C35D1-0.08 ± 0.76—
Mobility C36D1-0.08 ± 0.51—
Mobility C37D10.00 ± 0.63—
Mobility C38D10.00 ± 0.67—
Mobility C39D10.22 ± 0.83—
Mobility 30 day follow up0.47 ± 0.960.36 ± 0.98
Mobility 90 day follow up0.32 ± 0.760.43 ± 0.90
Self-Care Baseline1.12 ± 0.391.18 ± 0.56
Self-Care C2D10.05 ± 0.480.07 ± 0.67
Self-Care C3D10.02 ± 0.440.03 ± 0.60
Self-Care C4D10.05 ± 0.460.02 ± 0.64
Self-Care C5D10.05 ± 0.550.07 ± 0.72
Self-Care C6D10.05 ± 0.510.09 ± 0.63
Self-Care C7D10.07 ± 0.600.02 ± 0.70
Self-Care C8D10.10 ± 0.640.05 ± 0.62
Self-Care C9D10.15 ± 0.790.10 ± 0.58
Self-Care C10D10.11 ± 0.660.10 ± 0.65
Self-Care C11D10.09 ± 0.640.06 ± 0.69
Self-Care C12D10.09 ± 0.640.10 ± 0.55
Self-Care C13D10.05 ± 0.620.12 ± 0.56
Self-Care C14D10.04 ± 0.500.11 ± 0.61
Self-Care C15D10.00 ± 0.490.05 ± 0.52
Self-Care C16D10.00 ± 0.620.09 ± 0.59
Self-Care C17D10.02 ± 0.640.04 ± 0.53
Self-Care C18D10.10 ± 0.49-0.05 ± 0.49
Self-Care C19D10.00 ± 0.32-0.10 ± 0.44
Self-Care C20D10.00 ± 0.320.05 ± 0.60
Self-Care C21D10.03 ± 0.38-0.10 ± 0.44
Self-Care C22D10.00 ± 0.370.00 ± 0.59
Self-Care C23D10.06 ± 0.36-0.12 ± 0.49
Self-Care C24D10.07 ± 0.26-0.08 ± 0.64
Self-Care C25D10.11 ± 0.31-0.08 ± 0.64
Self-Care C26D10.12 ± 0.33-0.20 ± 0.63
Self-Care C27D10.08 ± 0.28-0.18 ± 0.60
Self-Care C28D10.10 ± 0.44-0.18 ± 0.60
Self-Care C29D10.14 ± 0.47-0.17 ± 0.58
Self-Care C30D10.10 ± 0.45—
Self-Care C31D10.10 ± 0.45—
Self-Care C32D10.06 ± 0.54—
Self-Care C33D10.13 ± 0.35—
Self-Care C34D10.08 ± 0.29—
Self-Care C35D10.08 ± 0.28—
Self-Care C36D10.08 ± 0.29—
Self-Care C37D10.27 ± 0.47—
Self-Care C38D10.20 ± 0.42—
Self-Care C39D10.22 ± 0.67—
Self-Care 30 day follow up0.34 ± 0.890.38 ± 0.81
Self-Care 90 day follow up0.30 ± 0.820.25 ± 0.82
Usual Activities Baseline1.40 ± 0.721.49 ± 0.81
Usual Activities C2D10.08 ± 0.810.06 ± 0.86
Usual Activities C3D10.02 ± 0.660.04 ± 0.77
Usual Activities C4D10.01 ± 0.76-0.01 ± 0.78
Usual Activities C5D10.10 ± 0.860.01 ± 0.89
Usual Activities C6D10.05 ± 0.71-0.03 ± 0.81
Usual Activities C7D10.05 ± 0.81-0.01 ± 0.83
Usual Activities C8D10.19 ± 0.760.07 ± 0.82
Usual Activities C9D10.19 ± 0.78-0.03 ± 0.82
Usual Activities C10D10.06 ± 0.750.03 ± 0.89
Usual Activities C11D10.11 ± 0.72-0.04 ± 0.74
Usual Activities C12D10.04 ± 0.71-0.03 ± 0.94
Usual Activities C13D10.02 ± 0.790.02 ± 0.80
Usual Activities C14D10.02 ± 0.730.00 ± 0.64
Usual Activities C15D10.10 ± 0.67-0.14 ± 0.67
Usual Activities C16D10.04 ± 0.65-0.06 ± 0.56
Usual Activities C17D10.00 ± 0.65-0.08 ± 0.63
Usual Activities C18D10.15 ± 0.57-0.14 ± 0.77
Usual Activities C19D10.13 ± 0.61-0.38 ± 0.67
Usual Activities C20D10.13 ± 0.57-0.25 ± 0.79
Usual Activities C21D10.17 ± 0.51-0.24 ± 0.70
Usual Activities C22D10.06 ± 0.44-0.22 ± 0.65
Usual Activities C23D10.06 ± 0.51-0.24 ± 0.66
Usual Activities C24D10.17 ± 0.47-0.38 ± 0.87
Usual Activities C25D10.25 ± 0.52-0.15 ± 0.99
Usual Activities C26D10.12 ± 0.43-0.30 ± 0.67
Usual Activities C27D10.12 ± 0.44-0.36 ± 0.67
Usual Activities C28D10.29 ± 0.56-0.18 ± 0.75
Usual Activities C29D10.14 ± 0.56-0.33 ± 0.65
Usual Activities C30D10.15 ± 0.59—
Usual Activities C31D10.05 ± 0.51—
Usual Activities C32D10.11 ± 0.76—
Usual Activities C33D1-0.07 ± 0.59—
Usual Activities C34D1-0.08 ± 0.67—
Usual Activities C35D10.08 ± 0.86—
Usual Activities C36D1-0.08 ± 0.67—
Usual Activities C37D10.00 ± 0.77—
Usual Activities C38D10.10 ± 0.57—
Usual Activities C39D10.22 ± 0.44—
Usual Activities 30 day follow up0.57 ± 1.160.40 ± 0.93
Usual Activities 90 day follow up0.41 ± 0.870.29 ± 0.94
Pain/Discomfort Baseline1.86 ± 0.861.84 ± 0.84
Pain/Discomfort C2D1-0.17 ± 0.86-0.13 ± 0.88
Pain/Discomfort C3D1-0.21 ± 0.76-0.16 ± 0.75
Pain/Discomfort C4D1-0.26 ± 0.87-0.29 ± 0.91
Pain/Discomfort C5D1-0.23 ± 0.87-0.26 ± 0.90
Pain/Discomfort C6D1-0.18 ± 0.82-0.22 ± 0.99
Pain/Discomfort C7D1-0.26 ± 0.87-0.20 ± 0.83
Pain/Discomfort C8D1-0.23 ± 0.86-0.19 ± 0.89
Pain/Discomfort C9D1-0.14 ± 0.75-0.18 ± 0.86
Pain/Discomfort C10D1-0.19 ± 0.87-0.18 ± 0.91
Pain/Discomfort C11D1-0.28 ± 0.93-0.11 ± 0.96
Pain/Discomfort C12D1-0.19 ± 0.83-0.09 ± 0.90
Pain/Discomfort C13D1-0.25 ± 0.840.04 ± 0.89
Pain/Discomfort C14D1-0.36 ± 0.82-0.02 ± 0.78
Pain/Discomfort C15D1-0.27 ± 0.800.00 ± 0.88
Pain/Discomfort C16D1-0.35 ± 0.86-0.03 ± 0.86
Pain/Discomfort C17D1-0.26 ± 0.730.08 ± 0.98
Pain/Discomfort C18D1-0.15 ± 0.690.00 ± 0.93
Pain/Discomfort C19D1-0.15 ± 0.80-0.05 ± 0.50
Pain/Discomfort C20D1-0.05 ± 0.72-0.15 ± 0.99
Pain/Discomfort C21D1-0.22 ± 0.72-0.05 ± 0.80
Pain/Discomfort C22D1-0.16 ± 0.78-0.28 ± 0.89
Pain/Discomfort C23D1-0.16 ± 0.73-0.18 ± 1.01
Pain/Discomfort C24D1-0.14 ± 0.790.00 ± 1.08
Pain/Discomfort C25D1-0.14 ± 0.850.00 ± 1.08
Pain/Discomfort C26D1-0.19 ± 0.750.20 ± 0.63
Pain/Discomfort C27D1-0.16 ± 0.800.00 ± 0.45
Pain/Discomfort C28D1-0.29 ± 0.850.18 ± 0.75
Pain/Discomfort C29D1-0.14 ± 0.77-0.08 ± 0.67
Pain/Discomfort C30D1-0.30 ± 0.73—
Pain/Discomfort C31D1-0.40 ± 0.68—
Pain/Discomfort C32D1-0.33 ± 0.84—
Pain/Discomfort C33D1-0.40 ± 0.74—
Pain/Discomfort C34D1-0.33 ± 0.78—
Pain/Discomfort C35D1-0.23 ± 0.60—
Pain/Discomfort C36D1-0.42 ± 0.67—
Pain/Discomfort C37D1-0.27 ± 0.65—
Pain/Discomfort C38D1-0.30 ± 0.95—
Pain/Discomfort C39D1-0.44 ± 0.53—
Pain/Discomfort 30 day follow up0.29 ± 1.140.32 ± 0.95
Pain/Discomfort 90 day follow up-0.03 ± 0.920.10 ± 0.94
Anxiety/Depression Baseline1.65 ± 0.821.64 ± 0.77
Anxiety/Depression C2D1-0.01 ± 0.83-0.11 ± 0.79
Anxiety/Depression C3D1-0.05 ± 0.68-0.01 ± 0.88
Anxiety/Depression C4D1-0.04 ± 0.74-0.08 ± 0.89
Anxiety/Depression C5D1-0.08 ± 0.77-0.07 ± 0.98
Anxiety/Depression C6D1-0.07 ± 0.750.00 ± 0.88
Anxiety/Depression C7D1-0.04 ± 0.80-0.04 ± 0.86
Anxiety/Depression C8D1-0.02 ± 0.770.06 ± 0.83
Anxiety/Depression C9D1-0.05 ± 0.810.03 ± 0.83
Anxiety/Depression C10D1-0.13 ± 0.840.13 ± 0.86
Anxiety/Depression C11D1-0.11 ± 0.810.21 ± 0.98
Anxiety/Depression C12D1-0.11 ± 0.830.17 ± 0.99
Anxiety/Depression C13D1-0.12 ± 0.740.20 ± 0.87
Anxiety/Depression C14D1-0.07 ± 0.780.22 ± 0.85
Anxiety/Depression C15D1-0.02 ± 0.620.19 ± 0.84
Anxiety/Depression C16D10.00 ± 0.710.06 ± 0.62
Anxiety/Depression C17D10.05 ± 0.720.15 ± 0.67
Anxiety/Depression C18D10.12 ± 0.780.00 ± 0.69
Anxiety/Depression C19D1-0.10 ± 0.78-0.05 ± 0.38
Anxiety/Depression C20D1-0.03 ± 0.710.05 ± 0.60
Anxiety/Depression C21D1-0.03 ± 0.84-0.05 ± 0.59
Anxiety/Depression C22D1-0.10 ± 0.540.17 ± 0.71
Anxiety/Depression C23D1-0.03 ± 0.710.18 ± 0.95
Anxiety/Depression C24D1-0.10 ± 0.620.00 ± 0.58
Anxiety/Depression C25D10.11 ± 1.030.15 ± 0.55
Anxiety/Depression C26D10.00 ± 0.800.20 ± 0.42
Anxiety/Depression C27D10.00 ± 1.040.09 ± 0.30
Anxiety/Depression C28D10.14 ± 1.060.09 ± 0.30
Anxiety/Depression C29D1-0.09 ± 0.970.25 ± 0.45
Anxiety/Depression C30D1-0.10 ± 0.85—
Anxiety/Depression C31D10.00 ± 1.08—
Anxiety/Depression C32D1-0.17 ± 0.86—
Anxiety/Depression C33D1-0.07 ± 0.88—
Anxiety/Depression C34D1-0.42 ± 0.51—
Anxiety/Depression C35D1-0.23 ± 0.60—
Anxiety/Depression C36D1-0.25 ± 0.45—
Anxiety/Depression C37D1-0.45 ± 0.52—
Anxiety/Depression C38D1-0.60 ± 0.84—
Anxiety/Depression C39D1-0.11 ± 0.60—
Anxiety/Depression 30 day follow up0.41 ± 1.270.45 ± 1.00
Anxiety/Depression 90 day follow up0.10 ± 0.760.24 ± 1.00
Visual Analog Scale Baseline71.50 ± 19.6072.65 ± 18.73
Visual Analog Scale C2D13.01 ± 15.831.67 ± 13.60
Visual Analog Scale C3D12.17 ± 15.192.07 ± 14.70
Visual Analog Scale C4D13.89 ± 16.603.27 ± 18.37
Visual Analog Scale C5D11.50 ± 17.203.74 ± 17.32
Visual Analog Scale C6D11.18 ± 17.611.95 ± 15.93
Visual Analog Scale C7D13.21 ± 15.602.73 ± 19.74
Visual Analog Scale C8D13.22 ± 19.721.73 ± 17.82
Visual Analog Scale C9D10.96 ± 17.322.49 ± 18.01
Visual Analog Scale C10D12.88 ± 20.071.48 ± 17.73
Visual Analog Scale C11D1-1.12 ± 18.131.50 ± 18.57
Visual Analog Scale C12D12.89 ± 21.701.36 ± 24.31
Visual Analog Scale C13D14.30 ± 17.810.88 ± 20.52
Visual Analog Scale C14D15.68 ± 25.252.20 ± 23.17
Visual Analog Scale C15D14.61 ± 23.63-1.84 ± 19.58
Visual Analog Scale C16D12.40 ± 18.263.44 ± 25.37
Visual Analog Scale C17D16.07 ± 24.082.35 ± 13.65
Visual Analog Scale C18D18.49 ± 24.624.59 ± 12.68
Visual Analog Scale C19D15.08 ± 21.115.95 ± 10.28
Visual Analog Scale C20D12.97 ± 25.524.15 ± 14.14
Visual Analog Scale C21D10.69 ± 19.396.29 ± 10.93
Visual Analog Scale C22D13.55 ± 15.243.28 ± 13.40
Visual Analog Scale C23D13.55 ± 14.934.12 ± 16.03
Visual Analog Scale C24D15.17 ± 16.196.85 ± 14.15
Visual Analog Scale C25D11.43 ± 20.297.15 ± 12.08
Visual Analog Scale C26D14.15 ± 16.831.20 ± 12.84
Visual Analog Scale C27D10.20 ± 20.584.73 ± 4.82
Visual Analog Scale C28D12.90 ± 18.302.36 ± 6.02
Visual Analog Scale C29D13.73 ± 15.743.58 ± 5.95
Visual Analog Scale C30D10.75 ± 15.87—
Visual Analog Scale C31D11.60 ± 16.83—
Visual Analog Scale C32D12.00 ± 15.78—
Visual Analog Scale C33D16.80 ± 17.07—
Visual Analog Scale C34D18.33 ± 17.91—
Visual Analog Scale C35D15.77 ± 16.63—
Visual Analog Scale C36D14.17 ± 17.20—
Visual Analog Scale C37D110.73 ± 14.55—
Visual Analog Scale C38D17.10 ± 17.70—
Visual Analog Scale C39D110.22 ± 11.42—
Visual Analog Scale 30 day follow up-7.79 ± 23.72-8.63 ± 20.32
Visual Analog Scale 90 day follow up-5.24 ± 19.73-4.34 ± 19.79
SecondaryPharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)

Ctrough was defined as the predose concentration at the end of dosing interval.

Time frame:
Predose on C2D1,C5D1,C9D1,C13D1,C17D1
Reported as:
Mean · micrograms/mililiter (ug/mL)
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
micrograms/mililiter (ug/mL)CAPOX+ Zolbetuximab
C2D138.6 ± 31.3
C5D174.1 ± 51.6
C9D199.6 ± 58.2
C13D1119.0 ± 55.6
C17D1147.0 ± 70.5
SecondaryNumber of Anti-drug Antibody (ADA) Positive Participants

Immunogenicity will be measured by the number of participants that are ADA positive.

Time frame:
Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up
Reported as:
Number · Participants
Number of Anti-drug Antibody (ADA) Positive Participants
ParticipantsCAPOX+ Zolbetuximab
C1D14
C2D28
C5D12
C9D11
C13D10
C17D10
30 Day follow up5
90 Day follow up1

Adverse events

Collected over All-cause mortality- From the start of randomization up to 61 months and 12 days Serious and non serious adverse events- From first dose up to 61 months and 12 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zolbetuximab180/254 (70.9%)123/254 (48.4%)249/254 (98%)
Capecitabine387/503 (76.9%)249/503 (49.5%)481/503 (95.6%)
Oxaliplatin387/503 (76.9%)249/503 (49.5%)481/503 (95.6%)
Placebo207/249 (83.1%)126/249 (50.6%)232/249 (93.2%)
Most frequent serious events
Showing 10 of 191
Most frequent serious events
EventZolbetuximabCapecitabineOxaliplatinPlacebo
VomitingGastrointestinal disorders15/25426/50326/50311/249
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/25423/50323/50313/249
NauseaGastrointestinal disorders11/25417/50317/5036/249
DiarrhoeaGastrointestinal disorders7/25417/50317/50310/249
Decreased appetiteMetabolism and nutrition disorders10/25413/50313/5033/249
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/25410/50310/5038/249
Platelet count decreasedInvestigations8/25414/50314/5036/249
Abdominal painGastrointestinal disorders3/25410/50310/5037/249
Pleural effusionRespiratory, thoracic and mediastinal disorders1/2548/5038/5037/249
Upper gastrointestinal haemorrhageGastrointestinal disorders7/25411/50311/5034/249
Most frequent other events
Showing 10 of 43
Most frequent other events
EventZolbetuximabCapecitabineOxaliplatinPlacebo
NauseaGastrointestinal disorders174/254297/503297/503123/249
VomitingGastrointestinal disorders164/254236/503236/50372/249
Decreased appetiteMetabolism and nutrition disorders103/254188/503188/50385/249
AnaemiaBlood and lymphatic system disorders90/254179/503179/50389/249
DiarrhoeaGastrointestinal disorders79/254162/503162/50383/249
Aspartate aminotransferase increasedInvestigations62/254136/503136/50374/249
Neutrophil count decreasedInvestigations71/254129/503129/50358/249
Platelet count decreasedInvestigations60/254121/503121/50361/249
Peripheral sensory neuropathyNervous system disorders57/254113/503113/50356/249
HypoalbuminaemiaMetabolism and nutrition disorders57/25492/50392/50335/249

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized to 1 of the treatment arms.

Age, Continuous
Age, Continuous(Years)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
Mean58.6 ± 12.156.7 ± 1357.6 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
Female9597192
Male159156315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
Hispanic or Latino10717
Not Hispanic or Latino242241483
Unknown or Not Reported257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
American Indian or Alaska Native000
Asian158158316
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9490184
More than one race000
Unknown or Not Reported257
Region (Asia vs Non-Asia)
Region (Asia vs Non-Asia)(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
Asia157158315
Non-Asia9795192
Number of organs with metastatic sites
Number of organs with metastatic sites(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
0-2 metastatic sites189188377
>=3 metastatic sites6565130
Prior Gastrectomy
Prior Gastrectomy(Participants)CAPOX+ ZolbetuximabCAPOX+ PlaceboTotal
Yes7575150
No179178357
08

Study locations

165 sites
  • Pacific Cancer Care
    Monterey, California 93940, United States
  • University of Kansas Cancer Center and Medical Pavilion
    Fairway, Kansas 66205, United States
  • Ochsner Clinic CCOP
    New Orleans, Louisiana 70121, United States
  • New Mexico Oncology Hematology
    Albuquerque, New Mexico 87109, United States
  • Weill Cornell Medical College (WCMC)
    New York, New York 10021, United States
  • Montefiore Medical Center (MMC)
    The Bronx, New York 10467, United States
  • Prisma Health Cancer Institute
    Boiling Springs, South Carolina 29316, United States
  • Parkland Hospital
    Dallas, Texas 75390, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology
    Houston, Texas 77030, United States
  • Utah Cancer Specialist
    Salt Lake City, Utah 84106, United States
  • Site AR54009
    Buenos Aires, Argentina
  • Site GB44005
    Northwood, Argentina
  • Site AR54006
    Pergamino, Argentina
  • Site AR54001
    San Miguel de Tucumán, Argentina
  • Site AR54004
    San Miguel de Tucumán, Argentina
  • Site AR54003
    Viedma, Argentina
  • Site CA15003
    Chicoutimi, Quebec, Canada
  • Site CA15002
    Rimouski, Quebec, Canada
  • Site CA15004
    Calgary, Canada
  • Site CN86034
    Fuzhou, Fujian, China
  • Site CN86037
    Fuzhou, Fujian, China
  • Site CN86032
    Haikou, Hainan, China
  • Site CN86012
    Zhengzhou, Henan, China
  • Site CN86029
    Changsha, Hunan, China
  • Site CN86043
    Hengyang, Hunan, China
  • Site CN86027
    Suzhou, Jiangsu, China
  • Site CN86046
    Wuxi, Jiangsu, China
  • Site CN86007
    Hangzhou, Zhejiang, China
  • Site CN86044
    Baoding, China
  • Site CN86035
    Beijing, China
  • Site CN86050
    Beijing, China
  • Site CN86025
    Bengbu, China
  • Site CN86002
    Changchun, China
  • Site CN86049
    Changchun, China
  • Site CN86053
    Changchun, China
  • Site CN86021
    Changzhou, China
  • Site CN86039
    Chengdu, China
  • Site CN86052
    Dalian, China
  • Site CN86054
    Dalian, China
  • Site CN86015
    Fuzhou, China
  • Site CN86001
    Guangzhou, China
  • Site CN86042
    Guangzhou, China
  • Site CN86051
    Haebrin, China
  • Site CN86036
    Hangzhou, China
  • Site CN86038
    Linyi, China
  • Site CN86016
    Nanjing, China
  • Site CN86045
    Nanning, China
  • Site CN86014
    Shanghai, China
  • Site CN86026
    Shantou, China
  • Site CN86047
    Shenyang, China
  • Site CN86017
    Shijiazhuang, China
  • Site CN86009
    Tianjin, China
  • Site CN86040
    Tianjin, China
  • Site CN86031
    Ürümqi, China
  • Site CN86004
    Wuhan, China
  • Site CN86005
    Wuhan, China
  • Site CN86013
    Xi'an, China
  • Site CN86030
    Xiamen, China
  • Site CN86011
    Xuzhou, China
  • Site CN86024
    Zhengzhou, China
  • Site HR38501
    Varaždin, Croatia
  • Site HR38502
    Zagreb, Croatia
  • Site HR38503
    Zagreb, Croatia
  • Site GR30001
    Athens, Greece
  • Site GR30004
    Heraklion, Greece
  • Site GR30003
    Larissa, Greece
  • Site GR30005
    Neo Faliro, Piraeus, Greece
  • Site GR30007
    Rio Patras, Greece
  • Site GR30002
    Thessaloniki, Greece
  • Site GR3006
    Thessaloniki, Greece
  • Site IE35301
    Dublin, Ireland
  • Site IE35302
    Dublin, Ireland
  • Site JP81007
    Fukuoka, Fukuoka, Japan
  • Site JP81008
    Akashi, Hyōgo, Japan
  • Site JP81003
    Kawasaki, Kanagawa, Japan
  • Site JP81001
    Yokohama, Kanagawa, Japan
  • Site JP81010
    Suita, Osaka, Japan
  • Site JP81005
    Utsunomiya, Tochigi, Japan
  • Site JP81002
    Chiba, Japan
  • Site JP81006
    Kashiwa, Japan
  • Site JP81004
    Kita-gun, Japan
  • Site JP81012
    Kōtoku, Japan
  • Site JP81009
    Matsuyama, Japan
  • Site JP81011
    Tsukiji, Japan
  • Site MY60001
    George Town, Malaysia
  • Site MY60004
    Kota Kinabalu, Malaysia
  • Site MY60002
    Kuala Lumpur, Malaysia
  • Site MY60003
    Kuala Lumpur, Malaysia
  • Site MY60005
    Kuala Lumpur, Malaysia
  • Site NL31004
    Groningen, Netherlands
  • Site NL31003
    Tilburg, Netherlands
  • Site PT35109
    Braga, Portugal
  • Site PT35110
    Coimbra, Portugal
  • Site PT35111
    Guimarães, Portugal
  • Site PT35102
    Lisbon, Portugal
  • Site PT35106
    Lisbon, Portugal
  • Site PT35105
    Porto, Portugal
  • Site PT35108
    Porto, Portugal
  • Site PT35104
    Santa Maria da Feira, Portugal

Showing the first 100 of 165 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yamaguchi K, Shoji H, Yasui H, Oki E, Sakai D, Hamaguchi T, Tsuji A, Oshima T, Tsuda M, Minashi K, Yang J, Guerrero A, Ueno Y, Matsangou M, Gourgioti G, Nakanishi Y, Furuki S, Kuwamoto K, Yamada S, Shitara K. Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials. Gastric Cancer. 2026 Jul;29(4):777-787. doi: 10.1007/s10120-026-01738-7. Epub 2026 May 7. PubMed 42095986 ↗
  • Stratton SP, Pang L, Pugh J, Kouzova M, Baldwin D, McDonald J, Lawrence-Glaze R, Moran S, Guerrero A, Moran D. Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW. Mod Pathol. 2025 Dec;38(12):100844. doi: 10.1016/j.modpat.2025.100844. Epub 2025 Jul 16. PubMed 40680855 ↗
  • Shitara K, Shah MA, Lordick F, Bang YJ, Ilson D, Van Cutsem E, Enzinger P, Kim SS, Klempner SJ, Moran D, Park JW, Bhattacharya P, Ajani JA, Xu RH. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol. 2024;20(26):1861-1877. doi: 10.1080/14796694.2024.2342107. Epub 2024 May 24. PubMed 38861294 ↗
  • Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. PubMed 37524953 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Oct 2022, 46 months.

Results were first posted in Jan 2025, 2 years 3 months after primary completion. A results delay was requested in Oct 2023.

Of 26 phase 3 interventional studies under Adenocarcinoma, half reached primary completion within 91 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 101. This study's 46 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2027, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2018
First posted
Aug 31, 2018
StartActual
Nov 28, 2018
Primary completionActual
Oct 25, 2022
CompletionEst.
Mar 31, 2027was Sep 2026
Results delay requested
Oct 23, 2023
Results first posted
Jan 27, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 30, 2026→Mar 31, 2027
Sep 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40680855 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40680855 ↗
    Study completion Sep 30, 2026→Mar 31, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03653507
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Nov 28, 2018
Primary completion
Oct 25, 2022
Completion
Mar 31, 2027 (estimated)
Results posted
Jan 27, 2025
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion